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Abstract 
 
Clinical presentation and risk factors of osteoradionecrosis 
Introduction: Osteoradionecrosis (ORN) of the jaws is defined as exposed irradiated 
bone that fails to heal over a period of 3 months without the evidence of a persisting 
or recurrent tumor. In the previous decades, numerous factors were associated with 
the risk of ORN development and severity. 
Aims: The purposes of this study were to present the data of the patients that were 
treated for ORN in the Department of Oral and Maxillofacial Surgery in Munich 
(LMU), to detect factors that contributed to the onset of ORN, to identify risk factors 
associated with the severity of ORN and finally, to delineate and correlate these 
factors with the personal, health and treatment characteristics of the patients. 
Material and Methods: A retrospective study was conducted during the period from 
January 2003 until December 2012 that included all ORN cases having been treated in 
the Department of Oral and Maxillofacial Surgery in Munich (LMU). The total 
sample was categorized in three groups according to stage and several variables were 
evaluated in an attempt to identify possible correlations between them and the 
necrosis severity. 
Results: One hundred and fifty three cases of ORN were documented. Among them, 
23 (15.1%) cases were stage I, 31 (20.2%) were stage II and 99 (64.7%) were stage III 
and all localised in the mandible. There was a predominance of the disease in the 
posterior region when compared to the anterior region. The majority of cases was 
addicted to alcohol and tobacco abuse and was suffering from Diabetes Mellitus 
(DM). All cases were treated with RT and 80.4% of them with concomitant 
chemotherapy. The initial tumor was predominantly located in the floor of the mouth, 
the tongue and the pharynx. Αpproximately two thirds of the cases occured either 
after dental treatment or due to a local pathological condition. Logistic regression 
analysis identified Diabetes Mellitus (OR: 4.955, 95% Cl: 1.965-12.495), active 
smoking (OR: 13.542, 95% Cl: 2.085-87.947), excessive alcohol consumption (OR: 
5.428, 95% Cl: 1.622-18.171) and dental treatment/ local pathological condition (OR: 
0.237, 95% Cl: 0.086-0.655) as significant predictors for stage III necrosis. Tumor 
  
 
 
 
size (T) (p<0.001), stage of the tumor (UICC) (p=0.001), concomitant chemotherapy 
(p<0.001), dental examination and treatment prior to RT (p<0.001) and the different 
causes of ORN (p=0.03) were statistically significantly associated with the severity of 
ORN. 
Conclusion: The aforementioned factors are predictive of ORN severity and can 
guide its prophylaxis and management. Based on these findings, prospective studies 
should be conducted in order to better understand risk factors associated with the 
development, severity and pathophysiology of ORN and improve treatment strategies 
for this complication of RT. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Zusammenfassung 
 
Klinische Präsentation und Risikofaktoren der Osteoradionekrose 
Einleitung: Die Osteoradionekrose (ORN) der Kiefer ist definiert als freilegender 
bestrahlter Knochen, der über einen Zeitraum von 3 Monaten nicht ausheilt, ohne 
Nachweis eines bestehenden oder rezidivierenden Tumors. In den letzten Jahrzehnten 
wurden zahlreiche Faktoren mit dem Risiko der Entwicklung einer ORN und ihrem 
Schweregrad assoziiert. 
Ziele: Die Ziele dieser Studie waren die Daten von Patienten, die wegen einer ORN in 
der Klinik für Mund-, Kiefer- und Gesichtschirurgie der LMU in München behandelt 
wurden, zu präsentieren, die Faktoren die zur Manifestation der ORN beigetragen 
haben, zu erkennen, die Risikofaktoren, die mit dem Schweregrad der ORN 
verbunden sind zu ermitteln und schließlich diese Faktoren mit der allgemeinen 
Gesundheits- und Behandlungscharakteristik der Patienten zu korrelieren. 
Material und Methoden: Eine retrospektive Studie wurde durchgeführt, um alle 
Fälle, die wegen einer ORN in der Klinik für Mund-, Kiefer- und Gesichtschirurgie 
der LMU in München im Zeitraum von Januar 2003 bis Dezember 2012 behandelt 
wurden, zu erfassen. Die Gesamtgruppe wurde gemäß den Erkrankungsstadien 
entsprechend in drei Gruppen eingeteilt und verschiedene Variablen wurden 
ausgewertet, um zu untersuchen, ob eine Korrelation zwischen ihnen und dem 
Schweregrad der Nekrose besteht. 
Ergebnisse: Einhundertdreiundfünfzig Fälle einer ORN wurden dokumentiert. Von 
ihnen entsprachen 23 (15.1%) Stadium I, 31 (20.2%) Stadium II und 99 (64.7%) 
Stadium III. Alle entwickelten sich im Unterkiefer. Es zeigte sich ein Vorherrschen 
der ORN im posterioren Anteil des Unterkiefers. Bei der Mehrzahl der Fälle lag 
Alkohol- und Tabakmissbrauch sowie ein Diabetes Mellitus (DM) vor. Alle Fälle 
wurden mit Strahlentherapie und 80.4% von ihnen mit Radio-Chemotherapie 
behandelt. Die Mehrheit der ursprünglichen Tumoren war im Mundboden-, Zungen- 
und Rachenraum lokalisiert. Ζwei Drittel der Fälle waren auf eine spezifische 
Ursache, einschließlich zahnärztlich chirurgischer Behandlungen oder einen lokalen 
pathologischen Zustand zurückzuführen. Die logistische Regressionsanalyse 
  
 
 
 
identifizierte Diabetes Mellitus (OR: 4.955, 95% Cl: 1.965-12.495), das aktive 
Rauchen (OR: 13.542, 95% Cl: 2.085-87.947), übermäßigen Alkoholkonsum (OR: 
5.428, 95% Cl: 1.622-18.171) und chirurgische Zahnbehandlungen/lokale 
pathologische Zustände (OR: 0.237, 95% Cl: 0.086-0.655) als signifikante 
Prädiktoren für das Stadium III der Nekrose. Die Tumorgröße (T) (p<0.001), das 
Tumorstadium (UICC) (p=0.001), die gleichzeitige Chemotherapie (p<0.001), die 
zahnärztliche Untersuchung und Behandlung vor der Strahlentherapie (p<0.001) und 
die auslösenden Ereignisse der Osteoradionekrose (p=0.03) waren mit der Schwere 
der Osteoradionekrosen statistisch signifikant verbunden.  
Zusammenfassung: Die oben genannten Faktoren sind prädiktiv für die Schwere der 
ORN und können zu einer Optimierung ihrer Prophylaxe und Therapie führen. Auf 
Basis dieser Erkenntnisse sollten prospektive Studien durchgeführt werden, um die 
Risikofaktoren für die Entwicklung von ORN, deren Schweregrad sowie 
Pathophysiologie besser zu verstehen und die Fähigkeit diese Komplikation zu 
behandeln, zu verbessern. 
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Chapter 1 
 
Oropharyngeal cancer 
Oropharyngeal cancers (OPCs) are defined as tumors of the oral mucosa, upper and 
lower alveolar process, hard palate, anterior two-thirds of the tongue, floor of the 
mouth, lips, larynx, pharynx, sinus maxillary and salivary glands (Schwenzer & 
Ehrenfeld 2011). 
OPCs consist major health concerns nowadays since oral cancer is the sixth most 
common cancer worldwide (Moore et al. 2000, Howlader et al. 2010). Ιncidences vary 
widely across geographical areas. The United Kingdom is demonstrating a relatively 
low incidence of 3500 cases annually. In parts of South East Asia like India a third of 
all male cancers originate in the oral cavity (Sunny et al. 2004).  In the United States, 
about 30.000 new cases of OPC are diagnosed every year and they cause more than 
8.000 deaths. About 26% of new OPC patients do not survive the first year after 
diagnosis and the 5-year survival rate of 52% has not improved for several years 
(Edwards at al. 2002). The vast majority of these cancers (85%) are squamous cell 
carcinomas and the remaining 15% are distributed among salivary gland, lymphoid 
and sarcomatous tumors (Peleg & Lopez 2006). The incidence of OPCs in Germany is 
2% among all malignancies (3.3% males, 1.4% females). The mean age of occurrence 
of OPCs is 61 years for males and 63 years for females (Schwenzer & Ehrenfeld 
2011). 
Several extrinsic and intrinsic risk factors contribute to the development of OPC. 
These include age, ethnicity, gender, habitual use of tobacco and alcohol, viral 
infections, bad oral hygiene and plaque, bacterial colonization, chronic infections and 
chronic mechanical irritation (Schwenzer & Ehrenfeld 2011). Fifty different potential 
carcinogens have been identified in tobacco, implicating smoking a significant risk 
factor for oral cancer (McDowell 2006). The synergistic effect of tobacco and alcohol 
results in 13-fold increased risk for developing oral cancer compared to either tobacco 
or alcohol use alone (Castellsague et al. 2004). Etiological factors like tobacco and 
alcohol consumption, as well as betel nut chewing, may be the reason for the 
geographical variations that were mentioned above (IARC 1985). Infection with 
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human papilloma virus (HPV) has also been identified as a potential risk factor for 
high incidence of OPCs in non-smokers. However, a relationship with oral cavity 
cancer is not yet established (Pintos et al. 2008). 
The great majority of OPCs are diagnosed in individuals over 65 years (Silverman 
2001) and males are 2 to 4 times more likely to develop oral cancer than women 
(McDowell 2006). With advancing age, there is a tendency for prolonged exposure of 
oral tissues to potential carcinogens, and aging cells may be more susceptible to DNA 
damage (McDowell 2006). The unusual rise of oral cancer in younger individuals and 
women without obvious risk factors has not been yet fully clarified. HPV is 
considered a probable cause. It is involved in the development of oral squamous cell 
carcinoma and is also associated with 30–40% of oral epithelial dysplasia and 
cancerous lesions (Schantz & Yu 2002, Kreimer et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 2  
 
Staging 
Clinical staging of malignant tumors is based on the TNM classification which was 
introduced in 1931 by the Swiss radiologists Schinz and Zuppinger and since then has 
been constantly revised in order to be adjusted to the latest clinical findings 
(Aggelopoulos & Alexandridis 2004, Schwenzer & Ehrenfeld 2011). 
T: describes size of the original (primary) tumor and whether it has invaded nearby 
tissue, 
N: describes nearby (regional) lymph nodes that are involved, 
M: describes distant metastasis. 
Although there are tumors that they don’t have a TNM classification such as brain 
tumors, most of the common tumors have their own TNM classification. For example 
the TNM classification for the OPCs is as follows: 
Based on tumor size are distinguished: 
• Tx: Tumor cannot be evaluated 
• Tis: Carcinoma in situ 
• T0: No signs of tumor 
• T1: Small tumor (≤ 2 cm) 
• T2: Bigger tumor (>2cm) 
• T3: Tumor reaches organ boundary (or >4cm) 
• T4: Tumor invades adjacent structures (for example bone, soft tissues of the 
neck) 
The lymph node involvement includes: 
• Nx: Lymph nodes cannot be evaluated 
• N0: Tumor cells absent from regional lymph nodes 
• N1: Regional lymph node metastasis present 
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• N2: Extensive unilateral or bilateral lymph node metastasis (for example the 
neck) 
• N3: More distant or numerous regional lymph nodes metastasis (>6cm or 
fixed) 
Distant metastasis includes: 
• M0: No distant metastasis 
• M1: Metastasis to distant organs 
Based on TNM classification the Union Internationale Contre le Cancer (UICC) 
developed and maintained a globally recognized standard (Staging) for classifying the 
extent of a cancer’s spread. Both TNM classification and Staging system are also used 
by the American Joint Committee on Cancer (AJCC) and the International Federation 
of Gynecology and Obstetrics (FIGO). Staging system is presented in the following 
table: 
Table 1: Staging system UICC 
Stage T N M 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
 
Stage III 
T3 
T2 
T3 
N0 
N1 
N1 
M0 
M0 
M0 
 
Stage IVA 
T4 
T4 
Any T 
N0 
N1 
N2 
M0 
M0 
M0 
Stage IVB Any T N3 M0 
Stage IVC Any T Any N M1 
 
 
 
 
  
 
 
 
Chapter 3  
 
Treatment of oropharyngeal cancers 
Treatment of OPCs needs a multifaceted approach and is divided into:  
• Curative therapy which means healing of tumor disease 
• Palliative therapy which means no healing of tumor disease but malignancy 
and the associated consequences like functional disability and pain become 
more bearable for the patient (Aggelopoulos & Alexandridis 2004, Schwenzer 
& Ehrenfeld 2011). 
Treatment involves surgery, chemotherapy, radiation therapy (RT), immunotherapy, 
monoclonal antibody therapy or a combination of these. The choice of therapy 
depends on the location and grade of tumor and stage of the disease, as well as the 
general state of the patient (performance status) (Aggelopoulos & Alexandridis 2004, 
Schwenzer & Ehrenfeld 2011, Turner et al. 2013). Early tumors (T1 and T2) are well 
managed with surgery or radiotherapy (RT). In many cases RT has the advantage of 
causing less impairment than surgical treatment. Moreover, RT is the alternative for 
patients with larger tumors who are unfit or do not want to undergo surgery (Turner et 
al. 1996). A number of experimental cancer treatments are also under development 
(Aggelopoulos & Alexandridis 2004, Schwenzer & Ehrenfeld 2011, Turner et al. 
2013). 
Goal of the treatment should be the complete removal of cancer without damage to 
the rest of the body. Sometimes this can be accomplished by surgery. However, its 
effectiveness is often limited due to the propensity of the cancers to invade adjacent 
tissues or to spread to distant sites by microscopic metastasis. On the other hand, 
chemotherapy and RT can unfortunately have a negative effect on normal cells 
(Aggelopoulos & Alexandridis 2004, Schwenzer & Ehrenfeld 2011). Despite their 
complications, two-thirds of patients with OPCs with local or regionally advanced 
disease are usually treated with both surgery and RT or with multimodality treatment 
(incorporating RT and chemotherapy) (Sciubba & Goldenberg 2006). 
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In spite of advances in treatment techniques of OPCs, there is still a high rate of acute 
and chronic oral complications that significantly affect the survival rate of patients 
(Sonis et al. 1978). 
3.1 Chemotherapy 
Chemotherapy consists of palliative chemotherapy, use of alkylating agents, plant 
alkaloids, antitumor antibiotics and toposiomerase inhibitors. Chemotherapy is used to 
treat cancers which are too large or have spread too far and can not be treated by 
surgery alone (Turner et al. 2013). The aim of the chemotherapy is to fight the tumor 
with local (local chemotherapy) or systemic (systemic chemotherapy) medicine, delay 
its development and relieve the patients of any symptoms. In cases of OPCs systemic 
chemotherapy is preferred. Substances which are usually used include 5-Fluoruracil 
(5-FU), Vincristin, Cisplatin, Carboplatin, Paclitaxel, Docetaxel, Methotrexate, 
Ifosfamide and Bleomycin (Schwenzer & Ehrenfeld 2011, Turner et al. 2013). These 
agents are used either alone as a monotherapy or in combination. 
Some forms of chemotherapy target all cells that divide rapidly and are not specific to 
cancer cells. However, some degree of specificity may come from the inability of 
many cancer cells to repair DNA damage, while normal cells generally can. Hence, 
chemotherapy has the potential to harm healthy tissue, especially tissues with a high 
repair rate (e.g. intestinal lining). These cells usually repair themselves after 
chemotherapy. It also affects the gastrointestinal tract, leads to leukocyte reduction 
and sickness. Sometimes the complications might be severe and cause termination of 
the therapy (Aggelopoulos & Alexandridis 2004, Schwenzer & Ehrenfeld 2011). 
3.2 Radiotherapy 
Radiation therapy, radiotherapy or radiation oncology is the medical use of ionizing 
radiation as part of cancer treatment to control or kill malignant cells (Lee et al. 2012). 
RT may be curative in some cases, but it may also be used as part of the adjuvant 
therapy in order to prevent tumor recurrence after surgery or to remove a primary 
malignant tumor (for example early stages of breast cancer). 
RT has the ability to control cell growth. Ionizing radiation damages DNA of 
cancerous tissues and leads to cellular death. This damage is caused by one of two 
  
 
 
20 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 3 
 
types of energy, photon or charged particle. In order to spare normal tissues such as 
skin or organs, through which radiation will pass, shaped radiation beams are aimed 
from several angles of exposure to intersect at the tumor. This provides a much larger 
absorbed dose there, than in surrounding healthy tissue. Apart from the tumor, 
radiation fields may also include draining lymph nodes if they are clinically or 
radiologically involved with the tumor, or if there is suspicion of subclinical 
malignant spread. Inclusion of normal tissue around the tumor is necessary since 
uncertainties can be caused by internal movement and movement of external skin 
marks relative to tumor position (Harrison et al. 2002, Bucci et al. 2005, Lutz et al. 
2011). 
3.2.1 Dose and fractionation 
The amount of radiation used in photon RT is called dose and is measured in gray 
(Gy). It varies and depends on type and stage of the tumor. For curative cases the dose 
for a solid epithelial tumor ranges from 60 to 80 Gy, while for lymphomas this dose 
varies from 20 to 40 Gy. Many factors are considered by radiation oncologists when 
selecting the dose. These include patient comorbidities, silmutaneous chemotherapy 
and period of RT (before or after surgery) (Harrison et al. 2002, Lutz et al. 2011).  
Delivery parameters of dose are determined during treatment planning. This is 
performed on computers using specialized treatment planning software. The radiation 
oncologist will design a plan that delivers a uniform prescription dose to the tumor 
and minimizes the dose to surrounding healthy tissues (Lutz et al. 2011). 
The total dose delivered to patient is fractionated for several reasons. First of all 
normal cells have time to recover between fractions while tumor cells are less 
efficient. Then fractionation allows tumor cells, which were in a relatively radio-
resistant phase of the cell cycle during one treatment, to cycle into a sensitive phase of 
the cycle before the next fraction is given, improving tumor cell kill. Fractionation 
programmes differ between therapy centers and oncologists. In Europe the typical 
fractionation schedule is 1.8-2 Gy per day, five days a week. In some cases two 
fractions per day are used at the end of the treatment. This schedule is known as 
concomitant boost regimen or hyperfractionation and is used on tumors which 
regenerate more quickly when they are smaller such as head and neck tumors 
(Mendenhall et al. 2003, Lutz et al. 2011, Lee et al. 2012). 
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A fractionation schedule increasingly used today is the hypofractionation. In this 
schedule the total dose is divided into large doses. The idea behind this is to minimize 
the possibility of cancer recover by not giving the cells enough time to reproduce and 
also exploit the unique biological radiation sensitivity of some tumors (Ferguson & 
Stevens 2007, Lee et al. 2012). Another well known fractionation schedule is 
Continuous Hyperfractionated Accelerated RT (CHART) which consists of three 
smaller fractions per day. In this approach a shorter duration of the therapy without 
reduction of total dose is achieved. A six-hour interval between fractions is important 
in order to allow time for normal tissues to repair (Ferguson & Stevens 2007). An 
alternative fractionation schedule, used to treat breast cancer is the Accelerated Partial 
Breast Irradiation (APBI). It involves two high-dose fractions per day for five days, 
compared to whole breast irradiation, in which a single, smaller fraction is given five 
times a week over a six-to-seven-week period (Ferguson & Stevens 2007, Lee et al. 
2012). 
3.2.2 Types of radiation therapy 
RT is divided into three groups: 
• External beam RT (EBRT or XRT) or teletherapy 
• Brachytherapy or sealed source RT 
• Systemic radioisotope therapy or unsealed source RT 
The main difference between these types is the position of radiation source; external is 
outside the body, brachytherapy uses sealed radioactive sources placed in the area 
under treatment and systemic radioisotopes are given by infusion or oral ingestion 
(Ferguson & Stevens 2007, Turner et al. 2013). 
EBRT includes three types: 
1. Conventional EBRT which is delivered via two-dimensional beams using 
linear accelerator machines 
2. Stereotactic radiation which uses focused radiation beams targeting a well-
defined tumor using extremely detailed imaging scans 
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3. Virtual simulation, 3- dimensional conformal RT (3D-CRT) and intensity-
modulated RT (IMRT) 
Particle therapy is a special sort of EBRT. According to this treatment energetic 
ionizing particles (protons or heavier ions) are directed at the target tumor. The 
advantage of this special therapy is that less energy is deposited into healthy tissue 
which surrounds the target area (Turner et al. 2013). 
Technical advances in RT and its delivery aim to address the tumor mass 
aggressively, while normal surrounding tissue is injured as little as possible (Hall & 
Wuu 2003, Galvin et al. 2004, Bucci et al. 2005). They include gamma knife, 
CyberKnife, linear accelerator X knife, IMRT, 3D-CRT and particle therapy. New 
radioisotopes such as cesium-137 and iridium-192 have replaced the initial radium 
sources improving systemic therapy (Ferguson & Stevens 2007). Positron emission 
tomography scans (PET-scan) lead to exact localization of the tumor, relative to 
proximal normal tissues. With use of 3D-CRT and IMRT, target volumes and critical 
normal tissues can be identified with accuracy. The 3D reconstruction of the patients’ 
anatomy enable the oncologist to get better diagnostic information about extension of 
tumor and its relation to normal tissues and develop a three dimensional treatment 
planning. With use of sophisticated computer software and hardware an accurate 
positioning of the patient is permitted (Hall & Wuu 2003, Galvin et al. 2004, Bucci et 
al. 2005, Ferguson & Stevens 2007). Another innovation in RT is the spacers. They 
decrease the exposure of normal tissues (for example lingual mandible) and minimize 
the incidence of complications after RT (Masahiko et al. 1988). These new 
innovations in addition to changes in fractionation patterns (hyperfractionation, 
accelerated fractionation) enable patients to profit from RT with minimal physical 
damage. 
 
 
  
 
 
 
Chapter 4 
 
Complications after chemotherapy and radiotherapy 
Ionizing radiation used for head and neck tumors affects oral mucosa, salivary glands, 
bone, dentition, masticatory musculature and also changes the quality and quantity of 
saliva, vascularity and oxygenation of bone and tissues and mucosal quality (Andrews 
& Griffiths 2001, Sciubba & Goldenberg 2006). As a result a number of 
complications can emerge after RT and chemotherapy (Koga et al. 2008a, 
Khojastepour et al. 2013, Turner et al. 2013). These complications can be divided into 
two groups (Table 2). 
Table 2: Acute and chronic complications of RT (Andrews & Griffiths 2001, Sciubba & Goldenberg 
2006, Koga et al. 2008a, Chrcanovic et al. 2010a, Khojastepour et al. 2013, Turner et al. 2013) 
Acute complications Chronic complications 
Oral mucositis Mucosal fibrosis and atrophy 
Infection: fungal, bacterial 
Salivary gland dysfunction: 
xerostomia, dental caries 
Salivary gland dysfunction: 
sialadenitis, xerostomia 
Soft- tissue necrosis 
Taste dysfunction Osteoradionecrosis (ORN) 
 
Taste dysfunction: dysgeusia, ageusia 
Muscular fibrosis, cutaneous fibrosis 
or trismus 
Infections: fungal, bacterial 
 
Other complications mentioned in the literature include microvascular alteration, local 
discomfort, oedema and periodontal attachment loss (Andrews & Griffiths 2001, 
Koga et al. 2008a, Chrcanovic et al. 2010a, Khojastepour et al. 2013). Reduction of 
mandibular cortex’s width and inferior alveolar canal’s dimensions are considered 
among postirradiation effects, which may be predictive of the risk of ORN 
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(Khojastepour et al. 2013). In severe cases, even death can occur (Marx & Johnson 
1987). Acute complications persist during treatment but resolve within the first weeks 
after completion of the treatment (Fischer & Epstein 2008). On the other hand, 
chronic complications prolong after treatment and result in lifelong morbidity. Oral 
complications after chemotherapy are of short duration (weeks to months), whereas 
complications after RT are more severe and serious (Turner et al. 2013). 
Several factors contribute to complications after RT. These include trauma to oral 
tissues during normal oral function and high cellular turnover rates of oral mucosa. As 
a result 90-100% of patients whose irradiation fields include the oral cavity will 
develop some degree of oral complications (Herrstedt 2000). The severity of 
complications is related also to several factors such as the dose and frequency of 
radiation as well as the volume of irradiated tissue and simultaneous use of RT and 
chemotherapy (Sciubba & Goldenberg 2006). Complications increase as the dose 
increases; the use of fractionation and the exposure of the patient to lower doses, 
reduce the side effects. Other factors that increase the severity of complications 
include preirradiation bone surgery, bad oral hygiene, alcohol and tobacco abuse and 
dental extractions after RT (Khojastepour et al. 2013). 
4.1 Oral mucositis 
Oral mucositis is an acute complication after RT, chemotherapy or a combination of 
both treatments. Oral mucositis is a result of direct contact between radiation and oral 
epithelium. Chemotherapy-induced mucositis depends on several factors such as 
patient’s age, degree of stomatotoxicity of the chemotherapeutic agent and preexisting 
oral conditions (Sonis 1998, Nishimura et al. 2012). Cinical characteristics include 
erythema, mucosal ulceration, oropharyngeal pain, and speech difficulties (Turner et 
al. 2013). About 80% of patients who take radiation will develop mucositis, with 
onset usually one week after start of the therapy (Kielbassa et al. 2006). It persists for 
two to three weeks after completion of RT (Million & Cassisi 1984, Dreizen 1990). 
Four weeks after end of the treatment, 90-95 % of the patients show complete healing 
of mucositis and sore throat is absent or minimal. Scarring may also develop (Million 
& Cassisi 1984, Epstein & Klasser 2006, Mosel et al. 2011, Nishimura et al. 2012). 
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Free radicals released by therapeutic agents cause a direct injury to the oral epithelium 
and can lead to this complication (Sonis 1998, Fischer & Epstein 2008). Mucous cells 
of the oral cavity, pharynx and larynx have a high turnover rate and low radiation 
resistance and respond early to radiation. Doses which are fractionated (for example 2 
Gy/day) lead to the development of mucosal erythema within one week (Million & 
Cassisi 1984). This erythema is caused due to a thinning of the epithelium and 
vascular dilation, inflammation and oedema of submucosa (Brown et al. 1975). As RT 
continues mucosa becomes denuded, with ulcerations and is covered with fibrinous 
exudates. The result is pain, burning and discomfort especially during eating. 
Depending on the extent of treatment fields, involvement of pharyngeal mucosa may 
produce difficulties in swallowing and speech (Dreizen 1990).   
Several attempts have been made to manage oral mucositis. Cryotherapy by sucking 
on ice chips before therapy has been used to reduce blood flow and stomatotoxic 
effects of chemotherapy (Cascinu et al. 1994). Use of granulocyte-macrophage colony 
stimulating factor, granulocyte colony stimulating factor and keratinocyte growth 
factor to improve local immune response and accelerate wound healing have also 
produced some beneficial effects (Hejna et al. 2001, Ryu et al. 2007). Poor oral 
hygiene, irritation from ill-fitting prosthesis and defective restorations can exacerbate 
oral ulcerations. Consequently, pre-therapy dental consultation to eliminate these 
potential risk factors will reduce oral morbidity (Sonis 1998). Use of chlorhexidine 
gluconate as an antimicrobial rinse may be beneficial by reducing oral microbial load 
and secondary infection. Topical application of lidocaine, benzocaine, or rinsing the 
mouth with a solution consisting of diphenhydramine, milk of magnesia, and a local 
anesthetic have beneficial palliative effects in oral mucositis patients. In severe cases, 
it may be necessary to administer systemic anti-inflammatory agents and opioid 
analgesics (Mosel et al. 2011). Many locally applied drugs have also been 
investigated to prevent or treat mucositis, which include sucralfate, vitamin E, 
chlorhexidine, anti-inflammatory substances, cytokines, alprostadil and dinoprostone, 
multidrug topical mouth rinses, folinic acid, and allopurinol (Herrstedt 2000). 
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4.2 Infections 
The risk for oral infections is increased during and after therapy of OPCs because oral 
microbial flora is altered by myelosuppression and oral cleansing property of saliva is 
diminished by reduced salivary flow. 
Fungal: Candida is a normal oral commensal in 34–68% of healthy individuals. 
Nevertheless, candidiasis is one of the most frequent oral infections during OPC 
therapy (Pyykönen et al. 1986, Ship et al. 2007, Fischer & Epstein 2008). Clinically, 
oral candidiasis presents as a removable white pseudomembrane or erythematous 
patch on the tongue, palate and labial commissures (Turner et al. 2013). It causes taste 
alterations, mucosal soreness and oral burning sensations. Heavy accumulations of 
candida may dislodge causing esophagitis, fungemia and pose aspiration risk to the 
patient. In rare circumstances, more invasive fungal organisms like mucormycosis and 
aspergillosis may affect myelosuppressed individuals and spread to the underlying 
bone.  
Two different forms of candidiasis can be distinguished: the acute form and the 
chronic form. The acute form is expressed as an erythema and burning sensation of 
the oral mucosa and may be mistaken for radiation mucositis. However, if erythema 
occurs bilaterally and symmetrically, in areas not within the radiation fields, 
candidiasis should be considered (Epstein et al. 1993). Fungal colonies may also be 
seen. In chronic forms of candidiasis, infection most commonly occurs in mouth 
corners or beneath prostheses (Dreizen 1990). 
Topical antifungal therapy is very effective (Epstein et al. 2002). Persistent or 
systemic spread of fungal infections can be controlled with systemic antifungal 
treatment. Systemic fungal infections are responsible for one third of deaths in 
immunocompromised patients (Epstein et al. 2002). As a result it is often necessary to 
administer prophylactic antifungals to reduce morbidity and mortality during OPC 
therapy. 
Viral: The most common cause of a viral infection in patients, who are treated for 
OPCs with chemotherapy and RT, is reactivation of latent herpes simplex virus type-1 
(HSV) (Schubert 1991, Mosel et al. 2011). Appearance in the oral cavity is atypical; it 
may become life threatening. In contrast to oral mucositis which occurs early, HSV 
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lesions generally appear about 18 days after initiation of therapy. Viral cultures are 
the most useful diagnostic tools for HSV infections. Seropositive OPC patients 
usually receive prophylactic treatment with acyclovir, an inhibitor of viral thymidine 
kinase (Epstein & Stevenson-Moore 2001, Lerman et al. 2008). Valacyclovir and 
famciclovir are alternative drugs with better bioavailability than acyclovir. In cases of 
acyclovir-resistant HSV infections, other therapeutic options like foscarnet or 
cidofovir are recommended (Lerman et al. 2008). 
Bacterial: Bacterial infections often arise from mucosal, gingival or odontogenic 
sources. Poor oral hygiene and hyposalivation increase oral microbial load thereby 
disrupting the balance of oral flora. Gram-positive organisms predominantly colonize 
oral cavity; but during OPC therapy, the inability to mount appropriate inflammatory 
response allows other pathogenic organisms to flourish leading to various 
opportunistic infections (Lee et al. 2011, Mosel et al. 2011). Conventional signs and 
symptoms of bacterial infections such as swelling, suppuration, and erythema may be 
muted or absent due to immune suppression. 
4.3 Hyposalivation and xerostomia 
Decreased salivary flow or hyposalivation is a common complication of OPC therapy. 
It is caused due to damage to salivary glands and presents as progressive xerostomia 
(dry mouth) (Mossman et al. 1982, Mossman 1983, Turner et al. 2013). Salivary flow 
can be decreased by about 50–60% in patients who undergo chemotherapy and by 
those who receive up to 20 Gy RT (Sweeney et al. 1997, Vissink et al. 2003b). The 
glandular architecture is replaced by ductal remnants and loose fibrous connective 
tissue which is moderately infiltrated with lymphocytes and plasma cells. This 
progressive glandular atrophy, fibrosis and reduced salivary output begin shortly after 
initial exposure and intensify thereafter (Kaplan 1985). 
Hyposalivation is usually reversible depending on the dose of radiation received. Only 
2.25 Gy has been shown to cause a 50 per cent reduction in the resting flow rate 
within 24 hours (Edgar & Mullane 1996). If all salivary glands are included in the 
treatment field, the result is viscous saliva (Million & Cassisi 1984) and salivation 
may be reduced by as much as 93% (Beumer et al. 1979a). When total dose is greater 
than 50 Gy and the salivary gland is in the field of radiation, hyposalivation is 
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irreversible (Eneroth et al. 1972, Vissink et al. 1988). By comparison, the cumulative 
dose used to treat head and neck solid tumours often exceeds 60 Gy, which can 
provoke the loss of at least 80 per cent of salivary gland function (Mossman 1983). 
Patients have difficulties to speak, smell, taste, chew or swallow and are more 
susceptible to oral infections, dental caries and periodontal diseases (Fischer & 
Epstein 2008). Composition and physiological functions of saliva are also affected, 
thereby reducing saliva buffering capacity, antimicrobial activity and ability to re-
mineralize damaged tooth enamel (Sonis et al. 1978). The oral mucosa is friable and 
susceptible to trauma, inflammation, and irritation (Fischer & Epstein 2008). The oral 
microbial population shifts to acidogenic microflora and increased concentrations of 
streptococcus mutans, lactobacillus and candida. As a result, patients become more 
susceptible to dental caries and opportunistic infections (Garcia et al. 2009). 
With advances in RT, an attempt is made to minimize these complications. If both 
parotid glands are spared during RT, then most of the patients report a little or no 
difference in quality and quantity of saliva and minimal long-term reduction in saliva 
is seen (Johnson & Moore 1983, Million & Cassisi 1984). If the upper limit of 
radiation field lies below the submental region, there is minimal long term reduction 
in salivary flow (Mossman et al. 1982). IMRT has been effective in reducing salivary 
gland damage and xerostomia (Jabbari et al. 2005). Fractionated radiation allows 
delivery of radiation to the tumor region at doses that allow normal tissue to repair 
sub-lethal DNA damage before the next dose is administered (Vissink et al. 2003b). 
Introduction of Amifostine, a radioprotective drug administered prior to RT has been 
very effective in minimizing hyposalivation during OPC therapy (Wasserman et al. 
2005, Sasse et al. 2006, Bardet et al. 2011).  
The management of hyposalivation includes the stimulation of the salivary gland 
during treatment in order to preserve salivary function by reducing glandular damage. 
Sucrose-free lemon drops or sugarless gum are nonpharmacologic agents used to 
stimulate salivary flow during and after RT. Use of cholinergic agonists like 
pilocarpine and cevimeline is also beneficial in stimulating salivary flow from 
residual glandular tissue (Gornitsky et al. 2004, Chambers et al. 2007). In cases of 
minimal residual salivary function, saliva substitutes can also be prescribed. Recently, 
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acupuncture has been shown to promote recovery from xerostomia in head and neck 
cancer patients treated with radiation (Garcia et al. 2009). 
4.4 Oedema, fibrosis, trismus and pain 
During the post-radiation period, scarring, fibrosis and oedema begin to appear. 
Although lymphatic channels are thought to be relatively radioresistant, radiation-
induced fibrosis impairs the patency of lymphatic and venous channels, resulting in 
lymphatic and venous obstruction. Oedema is prominent in the submental region, after 
the irradiation for anterior tongue and floor of mouth carcinoma and compromises 
tongue mobility and salivary control, incommoding denture wearing and speech 
articulation. Patients complain also for tongue and cheek biting. Furthermore, 
presence of fibrosis and oedema makes the detection of early recurrent lesions more 
difficult. Severity of oedema varies from day to day and from the time of the day 
(worse on waking and early morning) (Andrews & Griffiths 2001). 
5–38% of patients develop trismus after treatment for head-and-neck cancer (Sciubba 
& Goldenberg 2006). Patients who have been previously irradiated, those who receive 
both surgery and RT, and those who are being treated for a recurrence, are at higher 
risk of trismus than those receiving their first treatment. Trismus will cause damage 
and fibrosis of mastication muscles and also degenerative problems in the 
temporomandibular joint. These degenerative problems could mimic arthritic changes, 
and could be accompanied by inflammation and pain. If the symptoms are left 
untreated, degenerative processes will continue and become permanent (Sciubba & 
Goldenberg 2006). 
Clinically, trismus manifests as a slowly evolving inability to open the mouth to 
enable normal function. The mouth opening will be restricted, painless, and could be 
noted most readily during the first year after treatment. Speech articulation will not be 
adversely affected in most instances, but eating is often made difficult because of the 
restricted range of motion in all jaw movements. Restriction of mouth opening can 
result in compromised oral hygiene, which is particularly important in patients who 
also have radiation-induced xerostomia (Buchbinder et al. 1993, Sciubba & 
Goldenberg 2006). 
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Use of high-energy radiography beams and sophisticated multiple-field techniques 
can reduce the dose of radiaton to the temporomandibular joint and mastication 
muscles. The physicians should be able to identify the early signs of trismus. A simple 
test is the so-called three finger test. In this test, the patient is asked to insert three 
fingers into the mouth. Management of trismus includes also passive and active 
physiotherapy with simple and special devices. These include aggregated tongue 
blades or forced opening with finger pressure several times per day, as well as the use 
of more elaborate dynamic opening systems (such as TheraBite®) which are thought 
to be more efficient (Sciubba & Goldenberg 2006). Spastic reactions that cause 
abnormal jaw muscle closure can be controlled with botulinum toxin injections (Clark 
2003, Stubblefield et al. 2010). 
Neuropathic pain (25% of OPC patients) and neurosensory abnormalities can cause 
complications during the OPCs therapy. The reason for neuropathic pain is tumor 
invasion in peripheral or central nervous system or as a consequence of the treatment 
(Marchettini et al. 2001). Surgical resection of the tumor can also stretch or transect 
adjacent nerves causing neuropathic pain (Clark & Ram 2008). Management of the 
pain is achieved with use of pharmacologic agents such as anticonvulsants, 
antidepressants, local anesthetics, and N-methyl-D-aspartate receptor blockers (Baron 
et al. 2010). 
4.5 Taste dysfunction 
Alteration of taste sensation occurs as a result of the direct effect of radiation on taste 
buds and due to changes in the saliva (Mossman 1986, Nelson 1998, Spielman 1998). 
Dryness and damage to the taste buds caused by radiation lead to dysgeusia or ageusia 
and cause anorexia and malaise since interest in food is lost (Silverman 1990). In 
severe cases, reduction in the oral intake of fluids and nutrients can lead to 
dehydration and malnutrition (Mosel et al. 2011). This development may necessitate 
hospitalization to provide intravenous fluids or parenteral hyperalimentation 
(Andrews & Griffiths 2001).  
In most instances, taste acuity is partially restored 20-60 days after RT and gradually 
returns to normal or near-normal levels within one year after RT (Conger 1973, 
Tomita & Osaki 1990). There is usually no need for treatment. Prevention of taste loss 
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can best be accomplished through direct shielding of healthy tissue or placement of 
these tissues outside the radiation field by means of shielding or repositioning 
prostheses. As taste loss can result in weight loss, it is important to have a dietary 
counseling (Lees 1999, Erkurt et al. 2000). Level of hyposalivation is also important, 
since insufficient moistening and lubrication of oral tissues and food have a major 
negative impact on food intake and the ability of a patient to eat (Epstein et al. 1999a). 
Some patients may be left with residual hypogeusia after RT. Zinc supplements are 
reported to be helpful in increasing taste acuity in such patients. The acceleration of 
taste improvement in the post-RT period is probably of more benefit than the 
preservation of taste during RT (Vissink et al. 2003a). 
4.6 Radiation caries 
Radiation caries is a highly destructive form of dental caries with rapid onset and 
progression (Vissink et al. 2003b, Kielbassa et al. 2006). Lesions start on the labial 
surface at the cervical areas of teeth, including mandibular anterior teeth, which are 
usually very resistant to caries in nonirradiated populations. Dental caries can begin to 
develop as early as 3–6 months after treatment and progresses to complete destruction 
of all teeth over a period of 3–5 years (Jham et al. 2008). The developing tooth buds 
can also be destroyed if irradiated prior to mineralization. RT can also increase the 
severity of dental developmental disturbances induced by chemotherapy (Cubukcu et 
al. 2012, Turner et al. 2013).  
Radiation caries are categorized based on clinical and radiographic features. Type 1 
radiation caries is widespread superficial caries, type 2 is caries of the cementum and 
dentin at the cervical region and type 3 is dark pigmentation of the entire crown; 
combinations of these features may occur (Aguiar et al. 2009). 
Although a lot of investigators attribute radiation caries to the direct effects of 
radiation on teeth, others point to xerostomia, changes in salivary pH or alterations in 
microbial, chemical, immunological and dietary parameters (Vissink et al. 2003b, 
Kielbassa et al. 2006, Turner et al. 2013). The high incidence of radiation caries and 
its progression to the tooth cervix, which is seldom affected, is assigned to drastic 
reduction in salivation (Dreizen et al. 1977a, Pyykönen et al. 1986). As mechanical 
rinsing of teeth and buffering capacity of saliva are reduced (Brown et al. 1975), 
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saliva no longer protects teeth, and caries can attack any tooth surface. Adverse 
changes in the oral flora as a result of radiation constitute another important factor 
promoting caries. The number of S. mutans and Lactobacillus increase at expense of 
the less cariogenic S. sanguis, Neisseria and Fusobacterium (Brown et al. 1975). 
Although the immunological response of saliva against these micro-organisms 
improves, this effect is cancelled out by the low saliva secretion (Brown et al. 1975, 
Pyykönen et al. 1986). Nevertheless, the most likely cause of radiation caries appears 
to be a combination of those factors as well as the patient’s preirradiation 
susceptibility to caries, degree of postirradiation gingival recession, level of patient’s 
oral hygiene maintained, and intrairradiation dietary changes (Hayward et al. 1969). 
Until nowadays there are few reports of basic research on the topic of prevention and 
therapy of radiation caries. It is important to eliminate potential sources of dental 
infection prior to OPCs therapy (Lee et al. 2011, Mosel et al. 2011). A preventive 
caries program consisting of daily oral hygiene and daily topical 1.0% NaF gel 
application by means of custom-designed fluoride carriers, developed by Daly and 
Drane (1976) at the M.D. Anderson Cancer Center at Houston, TX (USA), has been 
studied extensively and forms the basis for the majority of other studies (Kielbassa et 
al. 2006). This programme dramatically reduced caries incidence and was also 
successful in arresting existing lesions, regardless of cariogenecity of the patients' diet 
(Dreizen et al. 1977a, Dreizen et al. 1977b). On the basis of a more than- 10-year 
experience with 935 head and neck cancer patients, Horiot et al. (1983) proved that 
this protocol was a highly reliable method for prevention of radiation caries. He also 
proved that the use of a toothpaste with a high fluoride content (3.0% NaF) twice a 
day was a good alternative, provided its pre-requisites (higher level of compliance) 
were well-understood by both clinician and patient. Because hyposalivation is 
irreversible in the majority of head and neck irradiation patients, application of 
fluoride must be continued indefinitely, regardless of chemical formulation and 
application method; otherwise caries will develop within months. Finally, since 
radiation caries is a lifelong threat to patients who have received radiation treatment 
for head and neck cancer, there is a lifelong need for meticulous oral hygiene and 
frequent fluoride applications to these patients (Vissink et al. 2003a). 
 
  
 
 
 
Chapter 5  
 
Prevention of complications before, during and after radiation 
therapy 
5.1 Before radiotherapy 
Oral problems which are associated with RT can be prevented or minimized through 
optimal management. A consultation with a dental team which has experience in care 
of patients with OPCs should be completed before onset of therapy (Simon & Roberts 
1991, Carl 1993). Poor oral hygiene, broken teeth, defective restorations and 
periodontal disease, are likely to cause complications during and after a course of RT. 
A thorough radiographic examination is also essential in order to determine the 
presence of inflammatory periapical abnormalities, periodontal status, other dental 
disease and tumour invasion of bone. A panoramic radiograph thus periapical or 
bitewing films (or both) are compulsory for pre-RT dental assessments. 
Communication with the patient’s physician regarding timing, nature and features of 
RT is also essential (Hancock et al. 2003). 
Teeth with periodontitis and bone loss may become exacerbated during OPC therapy 
resulting in local and systemic complications (Epstein & Stevenson-Moore 2001). 
Direct radiation injury to periodontal structures will compromise vascular supply, 
cause destruction of more periodontal tissues and promote bacterial invasion (Fujita et 
al. 1986, Chambers et al. 2007). Chemotherapy causes neutropenia, neutrophil 
dysfunction and impaired inflammatory response, which further delay tissue healing 
and a consequent loss of more periodontal tissues (Galler et al. 1992, Epstein et al. 
1998). It is important to assess the periodontal status of teeth and tissues within the 
field of radiation prior to therapy (Epstein & Stevenson-Moore 2001, Chrcanovic et 
al. 2010b).  All teeth, but especially those which are located within the radiation 
fields, should be closely evaluated. A study in the UK showed that only 11.2% of 
patients who reported regular visits in a general dentist before diagnosis of oral cancer 
  
 
 
34 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 5 
 
were considered to have no dental conditions that required treatment before RT (Lizi 
1992). 
Factors considered when estimating pre-RT dental status, include general condition of 
patient’s dentition (caries, periapical status, inflammatory periapical abnormalities), 
previous dental care, current oral hygiene, urgency of cancer treatment, planned 
therapy (radiation fields and dose) and prognosis of cancer therapy (cure or 
palliation). The dental management strategy should be more aggressive for patients 
with limited previous dental care, poor oral hygiene and evidence of past dental or 
periodontal disease (Hancock et al. 2003). 
5.2 During radiotherapy 
An increased monitoring of the oral cavity should be done during RT so as to decrease 
the severity of side effects. The patient’s self-care procedures should include frequent 
brushing with a soft-bristled toothbrush and fluoride toothpaste or gel to help prevent 
plaque accumulation and demineralization or caries of teeth (Carl 1993). The patient 
should be motivated to follow stringent plaque control. Dental health guidelines 
include: tooth brushing and dentifrice, mouth rinsing and flossing, fluoride 
supplementation with a fluoride gel, topical antimicrobial rinses such as 
Chlorhexidine 0,12 %, care of dentures during and after RT and care of lips and 
mouth. Use of dentures should be discontinued during and for a few weeks after RT in 
order to allow the radiation mucositis to heal (Turner et al. 2013). 
5.3 After radiotherapy 
After the end of RT, acute oral complications usually begin to resolve. Patients should 
continue to follow an oral health self-care programm in order to keep teeth and gums 
healthy and make the repair of any residual oral damage easier. Oral exercises should 
be continued or introduced to reduce the risk or severity of trismus. Furthermore, 
dietary counselling sessions may be appropriate for patients who must make long-
term dietary adaptations to accommodate permanent changes to their oral cavity 
produced by surgery and radiation. Competition of patients to support groups can also 
be a useful adjunct to patients’ return to optimal functioning. Long-term management 
and close follow-up of patients after RT is obligatory. Finally, a frequent and careful 
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examination to detect signs of recurrence or new primary malignant lesions is 
compulsory (Hancock et al. 2003). 
  
 
 
 
Chapter 6 
 
Osteoradionecrosis 
ORN is a devastating complication of RT in head and neck cancer. It was first 
described by Regaud (1922) and remains a clinical challenge until nowadays. 
Through the years several attemps have been made in order to best define ORN. 
Ewing (1926) was the first to use the term “radiation osteitis” to describe changes in 
bone after RT. In the following years several terms have been used to name these 
changes in bone such as radiation osteitis, ORN and avascular bone necrosis 
(Jereczek–Fossa & Orecchia 2002). In 1974 Guttenberg proposed the term “septic 
ORN of the mandible” to describe the stage of necrosis when irradiated bone becomes 
superficially infected ending up in high risk of involvement of deeper structures 
(Guttenberg 1974).  
In 1983 Marx defines ORN as “an area greater than 1 cm of exposed bone in a field of 
irradiation that had failed to show any evidence of healing for at least 6 months” 
(Marx 1983b). He also mentioned that there is only superficial contamination and no 
interstitial infection.  In 1987 Marx and Johnson proposed the following definition for 
ORN: “exposure of nonviable bone, which fails to heal without intervention” (Marx & 
Johnson 1987). Epstein et al. (1987b) defined ORN as “an ulceration or necrosis of 
the mucous membrane, with exposure of necrotic bone for more than 3 months”. 
Widmark et al. (1989) describe ORN as “a nonhealing mucosal or cutaneous ulcer 
with denuded bone, lasting for more than 3 months”. Together with Marx, they 
exclude conditions with necrotic bone but with an intact mucosa and skin. On the 
other hand, Store and Bosysen (2000) mention that not all cases of ORN involve 
exposed bone, but radiological evidence can be found in all cases. In 1997, Wong et 
al. define ORN as “a slow-healing radiation-induced ischemic necrosis of variable 
extent occurring in the absence of local primary tumor necrosis, recurrence or 
metastatic disease” (Wong et al. 1997). 
According to the most recent literature ORN of the jaws is defined as exposed 
irradiated bone that fails to heal over a period of 3 months without evidence of 
persisting or recurrent tumor (Marx 1983a, Marx & Johnson 1987, London et al. 
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1998, Teng & Futran 2005, Pitak- Arnnop et al. 2008, Khojastepour et al. 2013). At 
the time of diagnosis it might involve the bone superficially or deeply; it might be a 
process that progresses slowly or it might be in an active progressive state which can 
lead to a pathologic fracture (Thorn et al. 2000). The clinical consequences include 
pain, numbness, trismus, dysphagia, orocutaneous fistulae, pathological fractures, and 
local or systemic infections (Monnier et al. 2011). 
Taking into account all the above definitions the majority of authors agree to the 
following points (Wong et al. 1997, Chrcanovic et al. 2010a): 
1. Affected bone should have been irradiated. 
2. There should be absence of recurrent tumor. 
3. Mucosal breakdown or failure of healing should occur, resulting in bone 
exposure. 
4. Overlying bone should be “dead”. 
5. Presences of pathologic fracture, fistulation or cellulitis are not necessary in 
order to diagnose ORN.  
The duration of bone exposure has also been an issue of great controversy. Some 
authors do not comment on time of exposure (Epstein et al. 1992). Other authors 
recommend a 2-month period of exposed bone before diagnosis (Beumer et al. 1979b, 
Hutchinson et al. 1990, Tobias & Thomas 1996), or even 3 (Morrish et al. 1981, 
Beumer et al. 1983a, Harris 1992) and 6 months (Marx 1983a, Marx 1983b). There 
are also cases where a late diagnosis is present. Berger and Symington (1990) 
reported two late presentations: one 45 years after a radium implant and the other 38 
years after external beam treatment. 
Generally, a too short waiting period can lead to over-diagnosis as mucosal 
radionecrosis can occur without ORN. Moreover, any surgery and/or extraction 
performed, usually can take up to 1 month to heal. On the other hand, long periods 
such as 6 months are difficult to establish at clinical practice, and some intervention 
before this time is certainly needed. For these reasons it is proposed that the bone 
exposure should be of at least 3 months (Chrcanovic et al. 2010a). 
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6.1 Epidemiology 
According to literature the average age of patients with ORN is over 55 years (Grötz 
et al. 2001a, Reuther et al. 2003, Pitak-Arnnop et al. 2008, Almazrooa & Woo 2009). 
Mandibular ORN is predominant when compared to maxilla (ratio between mandible 
and maxilla is 24:1) (Perrier & Moeller 1994). 
Incidence of ORN varies in the literature. This variability is probably due to 
differences in study populations, observation periods, and existence of pretreatment 
dental assessment and dental management of cohorts. In the literature, incidence of 
ORN in head and neck–irradiated population was estimated to be 4.74-37.5% (Watson 
& Scarborough 1938, MacComb 1962, Grant & Fletcher 1966, Daly et al. 1972, 
Bedwinek et al. 1976, Murray et al. 1980b, Morrish et al. 1981, Epstein et al. 1987a, 
Withers et al. 1995, Reuther et al. 2003). Incidence decreased since 1990s (Berger & 
Bensadoun 2010). Recent studies show a decrease in incidence to <5%. This is 
attributed to the advent of megavoltage RT, improved dental preventive care, and 
improved radiation techniques including 3D-CRT and IMRT (Jereczek-Fossa & 
Orecchia 2002, Reuther et al. 2003, Studer et al. 2004). Clayman (1997) found an 
overall incidence of 11.8% before 1968 and 5.4% thereafter when megavoltage 
therapy became available. Wahl (2006) described a reduction in the incidence of ORN 
from 11.8% before 1968 to 5.4% from 1968-1992, and after 1997 to approximately 
3%. Recently, Lee et al. (2009) found that the frequency of ORN among 198 patients 
with either oral cavity or OPCs treated with radiation between the years 1990 and 
2000 was 6.6%. 
Although most authors report an incidence rate between 5-15% (Khojastepour et al. 
2013), rates as low as 0.4% and as high as 56% are also found in the literature 
(Jereczek-Fossa & Orecchia 2002, Reuther et al. 2003, Mendenhall 2004). In up to 
20% of patients where ORN persists and does not respond to aggressive treatment, 
bone damage is caused in fact by recurrent disease or a second primary tumour (Hao 
et al. 1999, Thorn et al. 2000). 
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6.2 Classification of osteoradionecrosis 
Several staging or scoring systems of ORN have been proposed. These systems are 
based on response to hyperbaric oxygen (HBO) therapy, degree of bone damage, 
clinical–radiological findings, length of bone exposure through the overlying skin or 
mucosa, and treatment needed. 
Coffin (1983) divided ORN cases in two groups: minor and major. Minor form was 
considered to be a series of small sequestra which separate spontaneously after 
varying periods of weeks or months. These small areas can be seen clinically but 
cannot be demonstrated radiologically. Major form was defined as necrosis occuring 
to an extent that involves entire thickness of the jaw, and a pathological fracture is 
inevitable. This form can be obviously seen radiologically and is extremely rare in the 
maxilla. 
Morton and Simpson (1986) subdivided ORN into three groups ‘minor’, ‘moderate’ 
and ‘major’. Minor ORN consisted of ulceration with exposed bone and a history of 
bony spicules which healed spontaneously over a period of months. Moderate cases 
consisted of exposed bone and small sequestra limited in nature and healing 
spontaneously with conservative treatment within 6 to 12 months. Major ORN 
consisted of large areas of exposed bone, with formation of large sequestra, possible 
fracture and sinus formation. These cases often progressed rapidly, lasting in excess 
of 1 year and often requiring radical treatment. 
In 1983 Marx proposed a new staging system for ORN which is used until nowadays. 
Advantages of this protocol include selection of patients who are able to respond to 
less aggressive treatments, use of minimum HBO exposure, resolve of the disease 
process, and preparation of patients’ tissues for reconstruction without further HBO 
(Peleg & Lopez 2006). 
According to this protocol if patient exhibits exposed bone in a field of radiation that 
has failed to heal for at least 6 months, and does not have a pathologic fracture, 
cutaneous fistula, or bony osteolysis to the inferior border, he or she enters stage I. In 
stage I, all patients receive 30 sessions of HBO at 2.4 ATA for 90 minutes at depth. 
After these 30 sessions, patients that respond to HBO alone (stage I responder) do so 
by demonstrating a softening of the radiated tissues and spontaneous sequestration of 
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exposed bone with formation of granulation tissue. Each so-called stage I responder 
undergoes an additional 10 HBO sessions and is then allowed to heal completely. 
Those patients who have not progressed after 30 sessions of HBO are advanced to 
stage II. This group represents patients with an amount of nonviable bone in excess of 
that capable of resorption and sequestration from HBO-induced angiogenesis alone. 
The nonviable bone requires surgical debridement in a manner so as not to 
compromise blood supply of adjacent viable, but radiation-damaged, bone. Stage II 
patient therefore undergoes transoral resection with limited soft tissue reflection. 
Surgical treatment includes extraction of involved dentition and a noncontinuity bone 
resection to clinically bleeding bone. Wound flaps are closed primarily and patient is 
given 10 postsurgical sessions of HBO. Tissues that heal without complication are 
challenged with prosthesis, as tissues in stage I responders. Tissues that dehisce and 
show additional exposed bone are advanced to stage III. Stage III patients represent 
those with a great quantity of nonviable bone and/or soft tissue unable to be managed 
by HBO-induced angiogenesis alone or HBO combined with local sequestrectomy. In 
addition to 30 presurgical HBO treatments, each stage III patient requires a continuity 
resection, stabilization, 10 postsurgical sessions of HBO, and plans for later (usually 3 
months) reconstruction (stage III-R). Stage III patients are therefore those who fail to 
respond in stage I and stage II and those who present initially with a pathologic 
fracture, cutaneous fistula, or osteolysis to the inferior border (Marx 1983a, Peleg & 
Lopez 2006). 
In 1987 Epstein et al. support a new staging system for ORN (Epstein et al. 1987a). In 
this system three different stages are distinguished based on clinical findings and not 
on response to HBO. Stage I represents healed, resolved ORN. Pathologic fracture 
may have occurred (Stage Ib), but the patient will have been reconstructed to provide 
continuity of the jaw. Stage II includes patients with chronic (>three months), 
persistent ORN. Lesion is not tender, remains stable in size, and neurologic symptoms 
of paresthesia and anesthesia, if present, are not progressive. The patient is either pain 
free or discomfort is well controlled. Patients may have a pathologic fracture (Stage 
IIb) and compromised jaw function; however symptoms are stable. In stage III, 
patient with progressive, active ORN manifest signs and symptoms of continuing 
disease. Resolution of the necrotic lesion and reversion to Stage I disease is goal of 
the treatment. 
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The scoring system proposed by Glanzmann and Gratz (1995) is focused on length of 
bone exposure and necessity of treatment. Clayman (1997) used a classification of 
ORN related to the overlying mucosa being intact or not. Clayman uses the term type 
I for cases in which bone lysis occurs under intact gingiva or mucosa and type II for a 
more aggressive type, called radiation osteomyelitis. In the latter type soft tissues 
break down, exposing the bone to saliva, and causing secondary contamination. It is 
suggested that type I cases heal with conservative therapy, while type II do not heal. 
In 2000 Store and Boysen introduced a new classification for ORN. It is based on 
presence or absence of clinical and radiological signs. In this system 4 different stages 
are distinguished: 0=mucosal defects only, I=radiological evidence of necrotic bone 
with intact mucosa, II=positive radiographic findings with denuded bone intraorally, 
III=clinically exposed radionecrotic bone, verified by imaging techniques, along with 
skin fistulae and infection (Store and Boysen 2000). 
The Marx staging system is the one used until today, although it relates to use of and 
response to HBO. The staging system of Epstein et al. (1987a) is an improvement, but 
is focused on the presence or absence of a pathologic fracture (Schwartz & Kagan 
2002). Under this rationale two new similar staging systems are designed which are 
simple, memorable and do not rely for the classification on any knowledge of clinical 
progress or response to treatment (Shaw & Dhanda 2011). These are the system of 
Schwartz and Kagan (2002) and the system of Notani et al. (2003). According to the 
system of Notani et al. patients are divided into grades I, II and III based on the extent 
of the ORN lesion. Grade I is defined as ORN confined to alveolar bone. Grade II is 
ORN limited to alveolar bone and/or the mandible above the level of mandibular 
alveolar canal. Grade III is ORN that extends to the mandible under the level of 
mandibular alveolar canal and ORN with a skin fistula and/or a pathologic fracture. 
6.3 Infected osteoradionecrosis 
Infection is a dreaded complication after ORN occurs. It is regarded as the most 
serious complication of ORN with a markedly increased risk for sepsis, bone fracture, 
severe impairment of quality of life and is called infected osteoradionecrosis (IORN) 
(Guttenberg 1974, Thiel 1989). Patients may have pain and fever. They also present 
with fistula and signs of inflammation of the surrounding mucosa or skin. 
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Several mechanisms contribute to the development of IORN. The damage of salivary 
glands through ionizing radiation, leads to salivary gland dysfunction and xerostomia. 
As a result sufficient saliva is not produced, which plays a crucial role in oral 
clearance, physiological bacterial microenvironment and the maintenance of mucosal 
integrity. The result is an increased predisposition to infections (Andrews & Griffiths 
2001).  
Several studies showed particularly high numbers of IORN cases positive for several 
microorganisms (Happonen et al. 1983, Andrews & Griffiths 2001, Annane et al. 
2004, Store et al. 2005, Hansen et al. 2006a). Significant increases have been noted 
for Streptococcus mutans and Lactobacillus species as well as Actinomyces (Andrews 
& Griffiths 2001). Among them, Actinomyces spp. was detected by several 
techniques in tissues from IORN patients since RT makes a favorable environment for 
this microorganism to flourish due to bone tissue alterations (Happonen et al. 1983, 
Curi et al. 2000a, Store et al. 2005, Hansen et al. 2006a). Studies of Curi et al. (2000a) 
and Hansen et al. (2006b) demonstrate that the overall prognosis of ORN is worsened 
in the presence of Actinomyces. Histological studies of IORN patients revealed that 
Actinomyces occurred in necrotic bone tissue and not in the oral mucosa or at the site 
of fistula (Hansen et al. 2006a). These organisms are involved in chronic, nonhealing 
inflammatory processes and purulent discharge, common characteristics of IORN. 
These bacteria are also associated with prolonged treatment duration (Hansen et al. 
2006a). Moreover, in the study of Curi et al. (2000a) patients with actinomycosis 
infection had significantly longer treatment period than those without infection.  
It was then debated whether detection of Actinomyces, which are normal inhabitants 
of the oral microflora, could be due to contamination or could be of importance in 
pathogenesis and course of the disease. In his study, Store et al. (2005) detected 
Actinomyces spp. by DNA–DNA hybridization in deep medullary bone specimens of 
patients suffering from ORN. Since these specimens had been obtained from areas 
completely covered by mucoperiostium, the authors suggested that the bacteria do not 
represent contaminants. 
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6.4 Clinical symptoms and diagnosis 
Diagnosis of ORN is based on clinical signs and symptoms. They include ulceration 
or necrosis of the mucosa with exposure of necrotic bone for longer than 3 months. 
Other symptoms include pain, trismus and suppuration in the area (Baker 1983, 
Epstein et al. 1987a, Nakatsuka et al. 1996, Shaha et al. 1997, Oh et al. 2009). 
Associated symptoms are neurologic symptoms such as pain, dysesthesia or 
anesthesia. Other symptoms such as fetor oris, dysgeusia and food impaction in the 
area are usually seen. Exposure of rough and irregular bone can result in physical 
irritation of adjacent tissues. Progression of ORN may lead to pathological fractures, 
intraoral or extraoral fistulae and local or systemic infection. Difficulties in mouth 
opening, mastication and speech arise frequently (Epstein et al. 1987, Jacobson et al. 
2010, Mücke et al. 2011a, Mücke 2011b). In patients treated with EBRT osseous 
alterations usually appear in the body of mandible (premolar and molar regions) 
whereas in those managed with brachytherapy, on the lingual or buccal surface 
(Hermans et al. 1996).  
Diagnosis of septic ORN appears to be easier. Primary symptom in this case is 
marked pain. A thorough clinical examination will reveal intra- or extraoral draining 
fistulae, ulcerations of the mucous membrane, exposed devitalized bone, 
hemorrhages, cellulitis or pathologic fractures. However, final diagnosis will be given 
through a biopsy in order to exclude metastatic cancer (Guttenberg 1974). 
6.5 Radiological findings 
Many radiological techniques can be used in order to detect ORN. They include 
radiographs, computer tomography (CT) scans, magnetic resonance imaging (MRI), 
Doppler ultrasound, nuclear medicine and near infrared spectroscopy (Chrcanovic et 
al. 2010a). 
Radiology is not very helpful in early stages of ORN (Miles 1992) and even in its 
advanced stages it does not necessarily relate to imaging features (Niebel & Neeman 
1957, MacDougall et al. 1963, Guttenberg 1974). In plain radiographs normal bone 
may be associated with large areas of exposed non-viable bone; conversely, if a small 
area is exposed the disease may spread into normal bone (Epstein et al. 1992). The 
described radiographic features range from normal appearance, to localized osteolytic 
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areas, extensive osteolytic areas, sequestra and fracture. Sockets after extraction of 
teeth will often remain visible for longer than twelve months after surgery. The most 
definitive radiographic alteration in early disease is that of increased radiodensity, 
followed by osteolysis in the affected area as well as a mixed radio-opaque 
radiolucent lesion, with radiolucent areas representing bone destruction (Guttenberg 
1974). 
The cheapest and readily available image is orthopantomogram (OPT), which can be 
supplemented with other extraoral or intraoral radiographs. ORN shows an undefined 
radiolucency without sclerotic demarcation which surrounds necrotic zone, but 
radiopaque areas can be identified when bone sequestra are formed. The visibility of 
ORN in OPTs requires a substantial alteration in mineral content and extensive 
involvement of bone, which only occurs in later stages (Epstein et al. 1987b). Ardran 
(1951) noted that a 30% loss of bone mineral content is necessary before any 
radiographic change can be seen. 
Although CT scans have similar limitations like traditional radiographs (Tobias & 
Thomas 1996), they show osseous abnormalities such as focal lytic areas, cortical 
interruptions and loss of the spongiosa trabeculation on the symptomatic side, 
frequently accompanied by soft tissue thickening. Such a picture may cause 
difficulties in differential diagnosis between ORN and recurrent tumour (Hermans et 
al. 1996). In MRI with gadolinium administration an abnormal marrow signal, cortical 
destruction and slight to mild irregular enhancement is demonstrated (Fujita et al. 
1991, Rabin et al. 1996, Store et al. 2000, Yoshioka et al. 2000). Advantages of MRI 
include excellent tissue contrast and high spatial resolution (Bachmann et al. 1996). 
Bone scintigraphy permits estimation of extension and location of the lesion. It shows 
high sensitivity (up to 100%) but low specificity (about 60%) for diagnosis of ORN 
(Bachmann et al. 1996). Scintigraphy using 99mTc-marked diphosphonates (99mTc-
MDP) allows highly sensitive depiction of mandibular lesions due to their altered 
phosphate metabolism. It can identify pathophysiologic changes in bone earlier than 
conventional radiography since scan changes reflect osteoblastic activity and good 
blood flow (Alexander 1976). Disadvantages of the method include low spatial 
resolution and overprojection by soft tissues, but they can be overtaken with use of 
single photon emission computerized tomography (SPECT) (Bachmann et al. 1996). 
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Finally, Positron Emission Tomography (PET) has been advocated as being able to 
differentiate between ORN and tumor recurrence (Minn et al. 1993). 
6.6 Histopathological findings 
Histologic findings of ORN include endarteritis, hyperemia, hyalinization, cellular 
loss, hypovascularization, thrombosis and fibrosis (Mainous & Hart 1975, Marx 1984, 
Marx & Johnson 1987). Some of these radiation effects, such as hyperemia, acute 
cellular loss and thrombosis are evident in the early phase, and other effects like 
hypovascularization and fibrosis occur 6-12 months after end of RT (Marx & Johnson 
1987). ORN is also characterized by destruction of osteocytes, marrow stem cells and 
blood vessels, resulting in absence of osteoblasts from bone margins, empty marrow 
spaces, marrow fibrosis, necrotic blood vessels and lack of new osteoid (Murray et al. 
1980b, Marx & Tursun 2012). Atrophic bone changes resemble those combined with 
atrophic changes of skin or mucous membranes (Howland et al. 1975). 
A histologic specimen of ORN of mandible shows bone with regular trabeculae but 
without osteoblastic activity. Marrow is replaced by sparsely cellular fibrous tissue 
admixed focally with bone debris. In addition, the specimen demonstrates a lack of 
inflammatory cells. In comparison, chronic osteomyelitis usually shows bone with 
irregular trabeculae due to osteoblastic and osteoclastic activity and bone marrow 
replaced by fibrous tissue. Moreover, inflammatory cells may be detected 
histologically in a chronic osteomyelitis (Reuther et al. 2003). 
6.7 Pathogenesis of osteoradionecrosis 
Over the past 80 years a lot of theories have been proposed about pathogenesis of 
ORN with consequent implications for its treatment (Khojastepour et al. 2013).  
In 1970, Meyer proposed a theory about pathogenesis of ORN (Meyer 1970). He 
hypothesized that osteonecrosis is a result of radiation injury to the bone and soft 
tissue followed by trauma (eg, tooth extraction or ridge irritation) and secondary 
infection (classic triad of radiation, trauma and infection). The vascular compromise 
induced by radiation sensitized bone to bacterial infiltration. Based on these findings 
he recommended operative debridement of necrotic bone and use of antibiotics as 
therapy. In 1976 Bump et al. mentioned that sepsis of devitalized bone produces a 
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virulent form of osteomyelitis with extensive tissue destruction (Bump et al. 1976). 
Titterington (1971) also mentioned that ORN is “an osteomyelitis secondary to 
irradiation”. Other authors stressed the role of Actinomyces, Candida, Streptococcus 
mutans and lactobacillus strains in pathogenesis of ORN (Haponnen et al. 1983, 
Keene & Fleming 1987, Epstein et al. 1991). 
However, there was little pathologic evidence to support Meyer’s hypothesis. He did 
not demonstrate through cultures or tissue sections a spread of osteomyelitis and 
microorganisms throughout the bone. He did not demonstrate septic destruction in 
avascular tissue, which cannot mount an inflammatory response (Marx 1983a). In the 
majority of ORN tissue specimens, bacterial infection and inflammation were absent 
and many cases did not continue as sepsis. Moreover, new studies (Pappas 1969, 
Beumer & Curtis 1979c, Rohrer et al. 1979) gave impetus to new ingestigations with 
respect to pathogenesis of ORN. 
As a result in 1983 Marx proposed a new biologic model for ORN (Marx 1983a). He 
suggested that ORN is not a primary infection of irradiated bone since bacteria were 
present only on the surface of bone and not within the bone. Radiation induced 
endarteritis, produced a vascular injury causing the bone and overlying soft tissue to 
become hypovascular, hypocellular, and hypoxic (the so-called “three H hypothesis”). 
In hypoxic, hypocellular, and hypovascular irradiated tissue, the ability to replace 
normal collagen loss or normal cellular loss is severely compromised or nonexistent. 
The result is a breakdown unrelated to microorganisms but related more to the degree 
of original radiation damage and rate of normal or induced cellular death and collagen 
lysis. Indeed, the role of trauma in initiation of ORN can now be seen as a single 
quantum of collagen lysis and induced cellular death. Mucosa in the irradiated area is 
thinner and more susceptible to mechanical injury and breakdown through eating, 
teeth brushing, hot food, poor oral hygiene and by effects of tobacco and alcohol 
(Vanderpuye & Goldson 2000). The wound which is created has an oxygen 
requirement and a demand for the basic elements of tissue repair that are beyond the 
capabilities of local tissue to provide. Furthermore, the incidences of ORN unrelated 
to trauma are consistent with a pathogenesis that does not necessarily include direct 
trauma as the etiologic agent. More likely, spontaneous ORN results, when mucosal 
breakdown or even breakdown of skin is due to tissue’s inability to keep up with 
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cellular turnover and collagen synthesis. It is related to use of implant sources and 
higher total radiation doses. Once any wound is created, it would be unrealistic to 
expect effective healing, considering the greatly increased demands for oxygen, 
energy, and nutrition in a tissue that could not maintain itself at its former level of 
metabolic demand (Marx 1983a). The mechanism is generally seen as an inability of 
both soft and hard tissue to keep up with cellular turnover and collagen synthesis 
(Epstein et al. 1987a). Sequence is as follows: (a) radiation, (b) hypoxic- 
hypovascular-hypocellular tissue (“three H” principle), (c) tissue breakdown (cellular 
death and collagen lysis exceed synthesis and cellular replication), and (d) nonhealing 
wound (a wound in which energy, oxygen, and metabolic demands exceed supply) 
(Marx 1983a, Oh et al. 2009). 
Marx et al. (1985) advocated for use of prophylactic and therapeutic HBO therapy in 
an effort to stimulate monocyte and fibroblast growth and increase the expression of 
vascular endothelial growth factor with secondary angiogenesis. After comparing 
antibiotic-treated versus HBO-treated radiated patients undergoing dental extractions, 
concluded that HBO therapy significantly lowered the risk of developing ORN. As a 
result, aim of treatment should be the reverse of hypoxia and the increase of 
vascularity and cellularity of tissues (Marx 1983a, Vudiniabola et al. 2000). 
However, there are few studies duplicating Marx’s results (Pasquier et al. 2004, Wahl 
2006). A recent randomized, controlled, double-blind trial reported no preventive 
benefit in a HBO treated group undergoing extractions. In this study, there was 
actually an increased risk of ORN in patients receiving prophylactic HBO (Annane et 
al. 2004, Mendenhall 2004). In 2004, Assael hypothesized that ORN occurs by the 
same mechanism as other types of osteonecrosis (eg, bisphosphonate-related 
osteonecrosis) and results from decreased osteoclastic bone resorption (Assael 2004), 
a mechanism that was also proposed previously from Jones and Boyde (1984) and 
supported by Bras et al. (1990). Increased subperiosteal bone deposition in ORN 
specimens and thickening of the jaw in radiated zones support this theory. Without 
osteoclasts to resorb the nonviable, radiated bone, healing is impaired (Al- Nawas et 
al. 2004). However, there is contradictory evidence to suggest that bisphosphonates 
may promote healing in patients with ORN (Delanian et al. 2005). Store et al. (2005) 
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used DNA hybridization and showed that bacteria may in fact play a fundamental role 
in pathogenesis of ORN, supporting Meyer’s original hypothesis.  
Another question that has also been an issue of controversy over the years is if ORN 
occurs primarily due to necrosis of bone or enveloping tissues. Store and Larheim 
(1999) confimed the existence of an initial central bone necrosis following radiation, 
with loss of the spongiosa, thinning and penetration of the cortex. This may explain 
the very special pathological pattern found in stage I cases, with radiological evidence 
of bone necrosis, even to the degree of a spontaneous fracture, still with full mucosal 
coverage (Store et al. 2000). 
A current theory proposes that ORN occurs by a radiation-induced fibroatrophic 
mechanism. In particular progression of ORN may be due to activation and 
dysregulation of fibroblastic activity that secondarily leads to necrosis of 
microvessels, local ischemia, and tissue loss. In the theory of Delanian (Delanian & 
Lefaix 2005, Delanian et al. 2011) ORN lesions are ultimately caused by an 
imbalance of bone resorption and bone deposition. Bone atrophy occurs in the setting 
of extensive fibrosis. Combination of osteoblast death, failure of osteoblast 
repopulation, and excessive proliferation of myofibroblasts results in bony matrix 
being replaced by fibrous tissue. Three distinct phases are seen (Vozenin-Brotons et 
al. 2003): the initial pre-fibrotic phase in which changes in endothelial cells 
predominate, together with the acute inflammatory response; the constitutive 
organised phase in which abnormal fibroblastic activity predominates, and there is 
disorganisation of the extracellular matrix and the late fibroatrophic phase, when 
attempted tissue remodeling occurs with formation of fragile healed tissues that carry 
a serious inherent risk of late reactivated inflammation in the event of local injury.  
After RT, endothelial cells are injured, both from direct damage by radiation and from 
indirect damage by radiation-generated reactive oxygen species or free radicals. 
Injured endothelial cells produce chemotactic cytokines that trigger an acute 
inflammatory response and then generate a further release of reactive oxygen species 
from polymorphs and other phagocytes (Dambrain 1993). Destruction of endothelial 
cells, coupled with vascular thrombosis, leads to necrosis of microvessels, local 
ischaemia and tissue loss. Loss of natural endothelial cell barrier allows seepage of 
various cytokines that cause fibroblasts to become myofibroblasts. These 
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myofibroblasts are characterised by unusually high rates of proliferation, secretion of 
abnormal products of the extracellular matrix and a reduced ability to degrade such 
components. Combination of osteoblasts’ death after irradiation, failure of osteoblasts 
to repopulate and excessive proliferation of myofibroblasts results in reduction in 
bony matrix and replacement with fibrous tissues. Ultimately, myofibroblasts undergo 
apoptosis, and even decades after RT, bone remains paucicellular, poorly vascularised 
and fibrosed (Riley 1994). 
In this case, resection of devascularized tissue would be insufficient to counteract the 
perturbations of bone metabolism. Such a mechanism may explain the possibility for 
ORN to persist and progress even after extensive mandible resection. Even if the 
surgeon notes vascularized margins after completion of resection, impaired 
functioning of fibroblasts, osteoclasts, and osteoblasts would continue on to 
exacerbate ORN progression (Zaghi et al. 2012). New antioxidant agents such as 
pentoxifylline and tocopherol have emerged on the basis of this theory as possible 
adjuvant treatments for ORN with promising results (Delanian & Lefaix 2004). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 7 
 
Risk factors of osteoradionecrosis 
Numerous factors in the literature are associated with the risk of developing ORN. 
These include total radiation dose, brachytherapy, fractionation, poor oral hygiene, 
alcohol, tobacco use, dental extractions, tumor size and location, staging (Morrish et 
al. 1981, Kluth et al. 1988, Jereczek-Fossa & Orecchia 2002, Reuther et al. 2003, 
Niewald et al. 2013). They can be divided into three main groups (Jereczek-Fossa & 
Orecchia 2002): 
1. Treatment-related factors (total dose, photon energy, brachytherapy, field size, 
fraction size, volume of the mandible irradiated) 
2. Patient-related factors (periodontitis, preirradiation bone surgery, bad oral 
hygiene, alcohol and tobacco abuse, bone inflammation, dental extraction after 
RT) 
3. Tumor-related factors (size of tumor, stage, anatomic tumor site, proximity of 
tumor to bone) 
Some of these factors are related with high risk of developing ORN whereas others 
with lower risk depending on population of each study and other parameters. For 
example optimization of nutritional status, use of steroids and limitation of total 
radiation dose minimize the risk of ORN (Goldwasser et al. 2007), while diabetes 
mellitus (DM), advanced primary tumor, alcohol and tobacco abuse are related with 
higher risk of ORN (Vanderpuye & Goldson 2000, Oh et al. 2009).  
According to the cause two different types of ORN can be distinguished: spontaneous 
and posttraumatic (Marx 1983a). These types are influenced from the different factors 
mentioned above and occurrence varies in different studies. For example Marx 
reported that 70% of ORN were posttraumatic (Horiot et al. 1981, Marx 1983a) 
whereas Hao et al. (1999) mentioned that 81% of patients had ORN due to iatrogenic 
cause. Spontaneous ORN is associated with doses higher as 60 Gy and its occurrence 
is decreased to the rate 6% or less due to use of newer techniques of radiation (3D-
CRT, IMRT) (Vissink et al. 2003b, Studer et al. 2004).  
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7.1 Technique of radiation 
Type of RT plays a significant role in the occurrence of ORN. The previous use of 
megavoltage and cobalt units during RT resulted in high accumulated doses to bone 
and higher incidence of ORN (Shaw & Butterworth 2011). Since the introduction of 
higher-energy RT, incidence of ORN has decreased from 10.31% to 6.28%. In the 
study of Meyer (1970) 5% of the patients treated with orthovoltage developed ORN 
while only 1-1.5% developed it with use of supravoltage. 
Risk of developing ORN is greatest when an interstitial implant is used as sole 
radiaton source (brachytherapy), less with combination technique and lowest with 
external beam alone. When the implant is close to the bone, the adjacent bone 
receives a high dose of radiation and is particularly susceptible to necrosis whereas 
bone far from implant preserves biologic activity. As distance from the implant 
increases, there is a rapid fall in radiation. For these reasons severity and extent of 
necrosis associated with an implant are less marked in these patients than those treated 
with EBRT (Murray et al. 1980b). As a result brachytherapy will cause more localized 
cases of grade I and II ORN, while damage caused by external RT is uniform within 
the radiation field resulting in extensive cases of grade III ORN (Notani et al. 2003). 
During the last years, new radiation techniques like IMRT and 3D-CRT were also 
studied by authors. IMRT reduces dose delivered to salivary glands and the rate of 
xerostomia, as well as other radiation related toxicities, providing superior target 
volume dose homogeneity and sparing of organs at risks. Many authors have 
mentioned the superiority of IMRT in reducing incidence and severity of ORN 
(Studer et al. 2006, Ben-David et al. 2007, Ahmed et al. 2009, Peterson et al. 2010, 
Gomez et al. 2011, Bhide et al. 2012, Gevorgyan et al. 2013, Tsai et al. 2013). 
Although encouraging, these results need further validation with longer follow-up. 
7.2 Fractionation 
The fractionation schedule mostly used nowadays is described as 1.8-2.0 Gy once 
daily, 5 days a week, over 4-8 weeks (Mendenhall et al. 2003). Changes in this 
fractionation schedule are connected with higher or lower incidence of ORN. Since 
1991, the increasing use of hyperfractionation and concomitant boost with better dose 
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homogeneity as well as moderately accelerated fractionated irradiation with modern 
techniques of three-dimensional conformal irradiation result in a lower risk of ORN 
(Studer et al. 2004). Many authors report lower incidence of ORN with use of 
hyperfractionation and accelerated fractionation with dose reduction, an expected 
finding due to total dose reduction (Parsons et al. 1988, Pigott et al. 1993, Mak et al. 
1995, Dische et al. 1997, Gwozdz et al. 1997, Fu et al. 2000, Mendenhall et al. 2000, 
Ang et al. 2001, Fallai et al. 2006, Skladowski et al. 2006, Cummings et al. 2007, 
Suwinski et al. 2008, Nabil & Samman 2012). Niewald et al. (2013) report in their 
study an increase in the frequency of ORN from 8.6% to 22.9% in patients treated 
with conventionally fractionated RT and hyperfractionated RT with higher total dose 
respectively.  
When using hyperfractionation, an interfraction interval >4.5 h is important. Niewald 
et al. (1996) showed an increase in the incidence of ORN (22.9%) after 
hyperfractionation with an interfraction interval of < 4.5 h. According to the study of 
Studer et al. (2004) as well as data of Mendenhall et al. (2000), Parsons et al. (1988) 
and Fu et al. (2000), the risk of ORN is <5% after a total dose between 72 and 80 Gy 
and an interfraction interval of 6h. 
7.3 Dose of radiation 
Results of different studies concerning total radiation dose given to patients are 
controversial. Some authors concluded that there was no association between 
radiation dose the patient received and stage of necrosis (Store & Boysen 2000) or 
that high dosage alone does not increase the risk of ORN (Kluth et al. 1988). The 
reason is that mandible shows a tolerance to irradiation doses ranging from 60 to 72 
Gy (Emami et al. 1991). Other authors propose and most of them agree that the higher 
the radiation dose the higher the risk of ORN (Beumer et al. 1972, Murray et al. 
1980a, Murray et al. 1980b, Morrish et al. 1981, Beumer et al. 1983a, Beumer et al. 
1984, Withers et al. 1995, Reuther et al. 2003, Chang et al. 2007, Lee et al. 2009, 
Gomez et al. 2011). Although most of ORN cases occur in the upper level of 
therapeutic doses, few can develop after lower dose of radiation (Kluth et al. 1988, 
Curi & Dib 1997). 
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Bedwinek et al. (1976) reported no cases of ORN at a radiation dose of 60 Gy or 
lower. Curi & Dib (1997) reported that 95.2% of the patients with ORN had received 
a radiation dose of 50 Gy or higher. Thorn et al. (2000) reported that 93% of ORN 
cases received a radiation dose of 64–68 Gy; Wong et al. (1997) reported that 
percentage of surgical removal was high for ORN that developed at >65 Gy. 
Goldwasser et al. (2007) concluded that patients receiving a radiation dose above 66 
Gy increased the risk of developing ORN by almost 11-fold. Other authors mention 
that an increase of radiation dose alone can not lead to increase in the incidence of 
ORN but its occurence is related to the synergic effect of radiation, fractionation and 
volume of irradiated tissue (Lozza et al. 1997, Jereczek-Fossa & Orecchia 2002, 
Reuther et al. 2003, Studer et al. 2006, Ben-David et al. 2007, Nabil & Samman 
2011). 
The dose of radiation influences also the occurrence of spontaneous and trauma-
induced ORN. Spontaneously occurring ORN is dose dependent (>60 Gy) and relates 
to the extent of radiation exposure (Marx & Johnson 1987, Glanzmann & Gratz 
1995), whereas trauma-induced ORN is more dependent on traumatic dental events 
such as periodontal disease, postirradiation teeth extraction, poor oral hygiene and 
inadequate denture irritation (Marx 1983b, Marx & Johnson 1987, Curi & Dib 1997, 
Thorn et al. 2000). Patients receiving higher radiation doses would therefore be more 
likely to develop spontaneously occurring ORN, whereas patients receiving lower 
doses would need trauma in the radiated tissue to initiate development of ORN (Thorn 
et al. 2000).  
7.4 Volume of irradiated tissues 
A correlation between the incidence of bone necrosis and the volume of irradiated 
mandible has been reported since many years (Beumer et al. 1984). Recent studies 
(Withers et al. 1988) of volume effect (based on field area rather than actual volume) 
in patients with oral cavity and oropharyngeal tumours were not able to demonstrate 
an increase in acute or late normal tissue injury with increasing treatment volume. 
Some previous analyses (Grant & Fletcher 1966, Shukovsky & Fletcher 1973, Spanos 
et al. 1976) of this relationship suggested that volume does influence normal tissue 
injury. Turner et al. (1996) proved that increasing target volume for doses less than 55 
Gy is a risk factor for ORN. It is therefore suggested that volume of irradiated tissue 
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together with radiation dose influence the incidence of ORN (Lozza et al. 1997, 
Reuther et al. 2003, Studer et al. 2006, Ben-David et al. 2007). 
7.5 Combination of radiotherapy with chemotherapy 
Chemoradiation therapy (CRT) is used in patients with positive margins or with 
evidence of extracapsular spread (Bernier et al. 2005). Also patients who are not 
suitable for surgery receive CRT as definitive treatment unless contraindicated. 
Chemotherapy is likely to weaken local immune response by damaging cellular 
immune system (Reuther et al. 2003). 
The synergic effect of CRT as a risk factor of ORN is also studied with different 
results (Nabil & Samman 2012). Some authors report higher incidence of ORN when 
CRT was used, (Hao et al. 1999, Jeremic et al. 2000, Denis et al. 2003, Cooper et al. 
2004, Budach et al. 2005, Semrau et al. 2006, Stenson et al. 2010) others when RT 
was used alone (Brizel et al. 1998, Huguenin et al. 2004, Racadot et al. 2008) whereas 
some authors reported no difference (Corvo et al. 2001, Fallai et al. 2006). Turner et 
al. (1996) proved that synchronous treatment with RT and Methotrexate 
chemotherapy is a significant prognostic factor for the development of ORN. 
7.6 Anatomy and localization of the tumor 
Anatomy of the bone is also a risk factor of ORN as mandibular ORN is much more 
common than ORN of the maxilla (Morrish et al. 1981, Beumer et al. 1984, Eggert et 
al. 1985, Kluth et al. 1988, Curi & Dib 1997, Thorn et al. 2000). The posterior molar 
region of the mandible is more affected than the anterior (Bras et al. 1990, Mounsey et 
al. 1995, Thorn et al. 2000, Reuther et al. 2003). The reasons proposed to explain this 
phenomenon are different. The mandible has a restricted localized blood supply, 
which is often completely within the radiation field, whereas the maxilla has many 
anastomoses located outside the area of irradiation (Cowgiel 1960, Hoffmeister et al. 
1969, Beumer et al. 1984, Thorn et al. 2000, Reuther et al. 2003). Moreover, the 
difference between bone density of maxilla and mandible, with mandible absorbing 
more amount of radiation may also explain the higher incidence of mandibular ORN 
(Cheng & Wang 1974, Mainous & Hart 1975, Morrish et al. 1981, Vanderpuye & 
Goldson 2000, Lambade et al. 2013). Posterior areas of mandible are almost always 
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included in the RT of both oropharynx and regional lymph nodes (Epstein et al. 
1987b, Thorn et al. 2000), as well as in the boosted RT fields. They also undergo 
maximal load during mastication and are often subjected to dental extractions 
(Jereczek-Fossa & Orecchia 2002). 
Localization of the initial tumor is mentioned as a risk factor of ORN. Generally, 
tumors of oral cavity or oropharyngeal region result in a higher incidence rate of ORN 
because of the inclusion of the mandible in the radiation field (Nabil & Samman 
2012). Patients with tumors related to the mandible have five times greater risk of 
developing ORN than those with anatomic sites other than the mandible (Murray et al. 
1980b). Oral cavity tumors, especially tumors of the tongue, floor of mouth, alveolar 
ridge or retromolar region contribute to higher risk for developing ORN after 
irradiation (Watson & Scarborough 1938, Curi & Dib 1997, Evensen et al. 2002, 
Notani et al. 2003, Reuther et al. 2003, van den Broek et al. 2006), since mandibular 
bone is directly involved in radiation fields and almost always an aggressive and 
radical surgical approach for tumor resection is needed (Curi & Dib 1997). On the 
other hand, tumors of sinonasal or nasopharyngeal areas present a higher risk for 
developing ORN in the maxilla (Tong et al. 1999, Cheng et al. 2006, Homma et al. 
2009), if any, because the maxilla is more resistant to ORN (Nabil & Samman 2012). 
Patients in whom RT portals include only the angle or ramus of mandible, like 
pharyngeal or laryngeal cancers, have a lower likelihood of developing ORN 
(Ferguson & Stevens 2007). When the primary tumor is adjacent to or is overlying 
bone, the risk of ORN is increased (Rohrer et al. 1979, Murray et al. 1980b, Tobias & 
Thomas 1996). 
7.7 Stage of tumor 
It has been reported that risk of developing ORN is greater in patients with advanced 
stage tumor (Bedwinek et al. 1976, Kluth et al. 1988, Reuther et al. 2003, Oh et al. 
2009, Tsai et al. 2013) and tumor invasion to adjacent bone (Murray et al. 1980c, 
Morrish et al. 1981, Epstein et al. 1987b). Turner et al. (1996) proved that bone 
involvement at the time of presentation, independent of tumor size and nodal stage, is 
related with higher incidence of ORN. The study of Curi and Dib (1997) concluded to 
the same result. 
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7.8 Alcohol and tobacco use 
Tobacco and alcohol abuse is clearly identified as a risk factor for ORN by many 
studies (Kluth et al. 1988, Schratter-Sahn et al. 1991, Glanzmann & Gratz 1995, Curi 
& Dib 1997, Thorn et al. 2000, Reuther et al. 2003, Shimizutani et al. 2005, Katsura et 
al. 2008, Tsai et al. 2013). In their study, Oh et al. (2009) showed that in patients with 
ORN who continued to smoke or consume alcohol, failure of conservative ORN 
management and ultimate requirement for surgical resection were more likely. Their 
mode of action is unexplained. Vasoconstriction which occurs owing to smoking may 
enhance the occurrence of mandibular hypovascularisation after RT (Katsura et al. 
2008). Furthermore, they probably potentiate the combined effects of other negative 
factors such as poor oral hygiene. Taking into account the above, encouragement of 
patients to quit smoking and alcohol consume is considered to be very important for 
the prevention of ORN. 
7.9 Dental status and oral health 
Occurrence and severity of ORN does not only depend on the extent of radiation 
damage to bone, but also on patient’s dental health (Nabil & Samman 2012). It is 
known that risk of developing ORN is increased in patients with poor oral health 
because more traumatic dental events are to be expected to these patients (Carl et al. 
1972, Regezi et al. 1976, Murray et al. 1980b, Murray et al. 1980c, Beumer et al. 
1984, Kluth et al. 1988, Bachmann et al. 1996, Katsura et al. 2008).This is further 
supported by findings that edentulous patients are at a lower risk of developing ORN 
(Murray et al. 1980b). 
Katsura et al. (2008) proved that oral health conditions that increased the risk of ORN 
were periodontal pocket depth >5mm, dental plaque score >40% alveolar bone loss 
>60% and a grade 3 radiographic periodontal status. Niewald et al. (2013) support 
that number of carious teeth and odontogenic cysts are significant prognostic factors 
for the occurrence of ORN. Murray et al. (1980a & 1980c) and Beumer et al. (1984) 
found a positive association between periodontal dental disease and occurrence of 
ORN. It can be concluded that periodontal disease should be eradicated before 
irradiation of oral tissues and the patient should eliminate plaque with correct tooth 
brushing technique in order to avoid spontaneous ORN cases. Finally, the importance 
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of good oral health and good dental management should be emphasized to patients 
undergoing radiation for head and neck cancer. 
7.10 Trauma before and after radiotherapy 
Trauma can be delivered to tissues in several ways; local trauma due to dentures or 
other reasons and surgically due to teeth extractions and major surgery related to 
treatment of the malignancy itself. Although until the 1970s and 1980s trauma was 
proposed as initiating factor of ORN, its role was since then questioned as many 
patients developed ORN without having evidence of previous trauma (Bedwinek et al. 
1976, Marx 1983a, Epstein et al. 1987b).  
7.10.1 Tooth extraction 
Tooth extractions play a crucial role in the pathogenesis of ORN (Hansen et al. 2006a) 
and they are proposed as the most common cause of trauma-induced ORN of the jaws 
in 60-89% of the cases (Murray et al. 1980a, Marx & Johnson 1987). The 
pathogenetic mechanism can be described as follows: a wound due to surgical 
procedure (dental extraction) requires protein syntheses which are obtained by cellular 
activity and vascular events (Maxymiw et al. 1991). Ionizing radiation promotes 
irreversible cellular and vascular damage resulting in hypoxic, hypocellular and 
hypovascular tissue. This fact can drastically affect the reparation process (Beumer et 
al. 1976, Beumer et al. 1983a, Beumer et al. 1983b, Beumer et al. 1984, Koga et al. 
2008a). Results regarding effect of tooth extraction to the occurrence of ORN are 
controversial. The highest incidence of ORN is observed in patients who have had 
extractions immediately before or immediately after RT (Epstein et al. 1987b) and 
after extractions of posterior mandibular teeth with roots lying below the mylohyoid 
line (Teng & Futran 2005). 
Regarding ORN cases related to extractions performed before RT, most studies show 
low incidence: Bedwinek et al. (1976) found 6.3% ORN cases, Regezi et al. (1976) 
2% after 311 dental extractions (49 patients), Epstein et al. (1987b) 5.4% in 454 
exodontias (92 patients), Sulaiman et al. (2003) 2.6% in 300 teeth removed in 77 
patients, Oh et al. (2004) 1.8% in 55 patients submitted to 99 extractions of third 
molars and Koga et al. (2008b) 0.5% in 1647 teeth removed in 363 patients. 
Interestingly, Starcke and Shannon (1977) and Makkonen et al. (1987) evaluated 515 
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exodontias (62 patients) and 45 exodontias (10 patients) respectively and there were 
no ORN cases related to dental extractions executed before irradiation. On the other 
hand, Carl et al. (1973), Beumer et al. (1983a), Sulaiman et al. (2003) and Chang et al. 
(2007) observed higher risk of ORN in dental extractions performed before RT 
compared with preservation of teeth. 
Considering extractions performed after RT, in the study of Koga et al. (2008b) from 
57 patients only 1 developed ORN (1.7%). This rate is lower than the 9.1% 
encountered by Horiot et al. (1981), 7.1% found in 42 patients submitted to 137 dental 
extractions by Epstein et al. (1987b), and 20.0% noted after extraction of 7 third 
molars in 5 patients by Oh et al. (2004). Furthermore, Sulaiman et al. (2003) observed 
1.8% ORN rates in 330 exodontias (107 patients). In several other studies 
postirradiation dental extractions are associated with high rates of ORN (Beumer et al. 
1972, Morrish et al. 1981, Beumer et al. 1984, Marx & Johnson 1987, Thorn et al. 
2000). However, Regezi et al. (1976), Makkonen et al. (1987), and Maxymiw et al. 
(1991) evaluated 10, 25, and 72 patients submitted to 23, 88, and 126 dental 
extractions, respectively, and there was no case of ORN related to dental extractions 
after head and neck irradiation. Other studies show similar results between dental 
extractions before and after RT (Epstein et al. 1987b, Reuther et al. 2003). 
Healing time after extractions until onset of RT is also a theme of great controversy 
among authors. Some of them propose that healing time is necessary for oral mucosa 
to recover and exposed bone to be completely covered before RT. This time should 
range from 10 to 21 days (Wildermuth & Cantril 1953, Stein et al. 1957, Shearer 
1967, Gehrig 1969, Hayward et al. 1969, Beumer et al. 1979b, Murray et al. 1980c, 
Beumer et al. 1983a, Coffin 1983, Epstein et al. 1987a, Marx & Johnson 1987, 
Maxymiw et al. 1991, Tobias & Thomas 1996, Curi & Dib 1997, Koga et al. 2008b). 
The proposition of this time interval comes from experimental work which has shown 
that it takes 3 weeks for osteoid to form in the sockets and epithelial repair to be 
complete after extractions (Peterson et al. 2010). Surgical extractions or extractions 
performed on old people require longer time for healing (Wildermuth & Cantril 1953, 
Beumer et al. 1972). Other authors (Starcke & Shannon 1977, Epstein et al. 1987b) 
report that healing time is not a statistically significant factor in the development of 
ORN or that calculations of healing time should take into consideration radiation 
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dose, location and status of tumor and extent and type of any surgical procedures 
performed (Daly et al. 1972). Generally, repairing time should not be extended for a 
long period that compromises oncologic treatment and prognosis (Beumer et al. 
1983a, Epstein et al. 1987b, Marx & Johnson 1987, Maxymiw et al. 1991, Tong et al. 
1999, Reuther et al. 2003). 
Concerning all the above the question is when to extract teeth, before, during or after 
RT. The worst moment for a tooth extraction is considered to be during RT, but the 
common belief to delay extractions after RT, in anticipation of tissue recovery with 
time, is wrong (Marx & Johnson 1987). All teeth that are severely diseased should be 
extracted at the pre-RT appointment (Chrcanovic et al. 2010b). After RT there is a 5-6 
month period of tissue repair and healing before the onset of progressive fibrosis and 
loss of vascularity. This phase is a much safer time to do necessary extractions in 
order to decrease the chances of ORN (Marx & Johnson 1987). 
Finally, most recent data show a downward trend of ORN risk after extractions (Nabil 
& Samman 2011). This finding together with that of Thorn et al. (2000) who found 
that out of 80 patients only 1 developed ORN outside the radiation field, indicates a 
great benefit of new radiation delivery and planning techniques such as IMRT and 
3D-CRT (Studer et al. 2006, Ben-David et al. 2007). Their ability to exclude jaws 
from radiation field could eliminate the risk of ORN. Moreover, extractions outside 
the radiation field can be performed safely. 
7.10.2 Placement of implants 
Placement of implants is also mentioned as a risk factor for developing ORN in the 
literature. Many changes in the irradiated bone increase the risk of ORN from implant 
placement (Nishimura et al. 1998). Rohrer et al. (1979) found that osteocytes in the 
direct path of irradiation are killed in both outer lamellar and Haversian bone. Blood 
vessels of Haversian canals may become obliterated and periosteum loses cellularity, 
vascularity, and osteoid formation. King et al. (1979) reported a reduced vascular 
patency in irradiated bone at 1 year after irradiation. Hematopoietic proliferation 
becomes sparse in the bone marrow and sinusoids become irregular in configuration 
and distribution (Knospe et al. 1966). Late effects of irradiation may result in the 
catabolic processes of bone exceeding anabolic processes, which eventually lead to a 
net reduction in the mineral content of irradiated bone (Finston et al. 1966). 
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Many authors mention different success rates and risk of bone necrosis after implant 
placement with or without use of HBO therapy (Granström et al. 1993, Taylor and 
Worthington 1993, Franzen et al. 1995, Arcuri et al. 1997). It is generally accepted 
that the risk of ORN should be considered when the region of placement is in the 
treatment field (Nishimura et al. 1998). It is relatively safe to place implants in 
irradiated mandibular sites if the dose is less than 55 Gy (Morrish et al. 1981, Beumer 
et al. 1983). In patients irradiated with more than 65 Gy, a course of HBO is 
recommended (Granström et al. 1992). Other factors such as dose per fraction, tissue 
response to irradiation and general health of patient should also be considered. 
7.10.3 Surgery related to tumor therapy 
Another source of trauma is resection surgery, which includes the field of irradiation, 
and certainly reduces blood supply to the area. Mandibulotomy or mandibulectomy 
prior to RT are mentioned to be significant risk factors in the occurrence of ORN 
(Marx & Johnson 1987, Celik et al. 2002, Lee et al. 2009, Monnier et al. 2011). 
Findings of other authors demonstrate that the more radical the resection of mandible 
during surgical therapy of tumor was, the sooner ORN occurred (Murray et al. 1980a, 
Marx & Johnson 1987, Reuther et al. 2003). 
7.10.4 Trauma due to denture 
Dentures may cause mucosal irritation and ulceration leading to ORN (Daly et al. 
1972). As a result it is important to avoid irritation from prosthetic appliances 
(Rankow and Weissman 1971). Some studies have recommended only mucosa-
supported prostheses (Curtis et al. 1976), others only implant-supported (Weischer 
and Mohr 1999) and others implant- and tissue-supported prostheses. 
Most patients can tolerate prosthesis without risk of bone necrosis. During RT the 
patient should wear dentures only for meals (Jansma et al. 1992a & 1992b, Mainous 
& Boyne 1974). Great care must be exercised in fabrication of dentures and in post 
insertion period. All patients must be followed regularly to ensure continued 
excellence of function and tissue relationship of their prostheses. In most 
maxillofacial centers the standard interval between irradiation and construction of 
dentures is 9 months to one year (Beumer et al. 1979b), but this time varies widely, 
depending on the individual. It has been suggested that six months is the average time 
required for irradiated tissues to return to as nearly normal a state as possible (Clark & 
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Howe 1976). This would seem a reasonable minimal interval to wait before 
commencing prosthodontic procedures. 
7.11 Time interval between radiation and occurrence of 
osteoradionecrosis 
Time interval between RT and onset of ORN varies in different studies and may 
influence the severity of ORN (Rathy et al. 2013). Occurrence of ORN varies from 
one month to 14 years after RT (Morrish et al. 1981, Curi & Dib 1997, Epstein et al. 
1997, Reuther et al. 2003, Studer et al. 2004, Sciubba & Goldenberg 2006, Studer et 
al. 2006, Almazrooa & Woo 2009, Nabil & Samman 2011), but risk remains until the 
end of patient’s natural life (MacComb 1962). Most of cases occur during the first 
postradiotherapeutic year (MacComb 1962, Beumer et al. 1972, Daly & Drane 1972, 
Starcke & Shannon 1977, Murray et al. 1980a & 1980b, Beumer et al. 1984, Epstein 
et al. 1987a, Kluth et al. 1988). Other authors mention that the majority of cases occur 
within 3 years after RT (Gowgiel 1960, Marx & Johnson 1987, Clayman 1997, Thorn 
et al. 2000, Notani et al. 2003, Chang et al. 2007). 
The later ORN develops and the higher the dose radiation dose, the more it progresses 
(Notani et al. 2003). The explanation is a reduction in biologic activity which 
develops irreversibly with time after RT (Bedwinek et al. 1976, Larson et al. 1983, 
Marx 1983a & 1983b, Epstein et al. 1987a). This means that ORN which develops 
early may have still more biologic activity to heal sponataneously and lesion will be 
localized. On the other hand, late-onset may have less biologic activity and lesion will 
become serious. 
Marx and Johnson (1987) observed that most spontaneous presentations of ORN 
occurred between 6 months and 2 years after RT, whereas the risk of developing 
trauma-induced ORN lasts indefinitely. This is also shown by other authors (Epstein 
et al. 1987a, Curi & Dib 1997, Thorn et al. 2000). Thorn et al. (2000) discovered that 
most late-onset ORN incidents were trauma-induced with the latest being 16 years 
after RT. Marx and Johnson (1987) found a bimodal peak of incidence relating to 
trauma-induced ORN and showed that the second peak starts after 2 years and peaks 
at 5 years. This peak is probably due to the increasing number of patients needing 
extraction due to tooth breakdown a few years after RT. 
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Treatment of osteoradionecrosis 
Although many reports have been published on the management of ORN, it remains a 
difficult and challenging problem. Various different treatment methods of ORN have 
been reported (Guttenberg 1974, Beumer et al. 1984, Nakatsuka et al. 1996, Shaha et 
al. 1997, Aitasalo et al. 1998, Oh et al. 2009) depending on several factors such as 
presentation of necrotic lesion, response to conservative nonsurgical therapy, general 
health of the patient, prognosis for successful management of the cancer, wishes of 
the patient, dose of irradiation and time interval after RT (Epstein et al. 1987a, 
Kawahara et al. 1987, Notani et al. 2003).  
Management of ORN includes medical and surgical intervention. Medical 
management is the conservative treatment and includes oral care, local debridement, 
ultrasonography, or HBO. Surgical management includes resection of the necrotic 
bone with reconstruction and is indicated if conservative therapy does not resolve the 
pathologic condition (Guttenberg 1974) or in late stages of ORN which include 
fistula, fracture and a large area of exposed bone (Hao et al. 1999, Lambade et al. 
2013). Some investigators agree that initial treatment of ORN should be conservative, 
since failure of this course can always be followed with a more radical approach 
(Niebel & Neeman 1957, MacComb 1962, Hahn & Gorgill 1966). Others believe that 
a radical approach should be instituted at initial diagnosis (MacDougall et al. 1963, 
Marchetta et al. 1967). Most of the authors advocate a treatment approach according 
to stage of necrosis (Jacobson et al. 2010, Gevorgyan et al. 2013). 
Conservative treatment is usually used for almost all patients; however, the ultimate 
need for radical resection after conservative treatment is reported to be as high as 70% 
to 83% (Bedwinek et al. 1976, Larson et al. 1983, Marx 1983a & 1983b). Protocols 
combining surgery and HBO have shown success rates 15-90% (D’Souza et al. 2007, 
Shaw & Dhanda 2011, Shaw & Butterworth 2011) but are also denoted as being 
impractical by other authors because of costs and time (Epstein et al. 1987b, Wong et 
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al. 1997). Recent studies have shown good results with use of stem cells in order to 
promote healing (Thom et al. 2006). 
8.1 Conservative treatment 
Conservative nonoperative management is usually recommended, especially in case 
of early and localized lesions or a lesion that is not progressing with minimal 
symptoms. Conservative surgical management can also be useful in some cases 
(Guttenberg 1974, Beumer et al. 1984, Nakatsuka et al. 1996, Shaha et al. 1997, 
Aitasalo et al. 1998, Oh et al. 2009). Conservative treatment includes nonoperative 
(for example improvement of oral hygiene, antibiotics, and analgesics) and surgical 
management (for example debridement and sequestrectomy), as well as HBO therapy. 
During conservative management, local irritants such as alcohol, tobacco, smoking, 
and ill-fitting dentures should be avoided, and regular dental visit are advised. Initial 
approach should be with medication and local wound care only (Chrcanovic et al. 
2010b). Oral hygiene is essential, including use of 0.2% aqueous chlorhexidine 
mouthwashes after meals (Scully & Epstein 1996) and constant saline mouthwashes. 
Debris should be washed or irrigated away and sequestra should be allowed to 
separate spontaneously or gently removed, since any surgical interference may 
encourage extension of necrotic process. Other authors state that if sequestration is 
present the decision should be surgical removal and in this case success rate is 75% 
(Wong et al. 1997, Lambade et al. 2013). Curi and Dib (1997) advocate 
sequestrectomy when a sequestrum is identified by radiologic techniques.  
Analgesics and antiinflamatory drugs are prescribed when necessary (increasing signs 
and symptoms of pain, discomfort, etc.). Although ORN is not primarily an infectious 
process and tissues are hypovascular, limiting the success of systemic antimicrobial 
agents, tetracyclines have been recommended because of their selective uptake by 
bone (Rankow & Weissman 1971, Coffin 1983, Store & Granström 1999, Teng & 
Futran 2005). However, access to avascular bone is questionable, making tetracycline 
inactive. Penicillin has also been used, because of involvement of oral bacteria in the 
superficial contamination (Daly et al. 1972, Marx et al. 1985). Unacid is also an 
effective antibiotic in the prophylaxis and treatment of ORN (Heibel et al. 2005). 
Metronidazole 200 mg, three times daily or other broad spectrum antimicrobials can 
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also be given in cases of severe infection or where anaerobes are implicated (Beumer 
et al. 1983b, Marx 1984, Harris 1992).  
Conservative strategies have been reported by authors to spare patients resection in 
77-96% (Rankow & Weissman 1971, Beumer et al. 1984, Epstein et al. 1987a). If 
complete resolution is not achieved, asymptomatically preserved function may still be 
acceptable especially in patients with advancing age or those who wish to avoid 
surgery (Epstein et al. 1987a). For some patients, surgery is inappropriate, and they 
are more appropriately treated with conservative measures because of age and poor 
health. 
8.1.1 Hyberbaric oxygen therapy 
HBO therapy is the intermittent, usually daily, inhalation of 100 per cent oxygen at a 
pressure greater than one atmosphere absolute (ATA) (Clanci & Sato 1994). Thus, it 
is a means of increasing dose of oxygen dissolved in plasma and delivered to tissues. 
HBO treatment developed from studies carried out by U.S. Navy medicine units 
investigating management of decompression sickness and arterial gas embolism. HBO 
Committee of the Undersea and Hyperbaric Medical Society currently recommend 
HBO for several uses, including air and gas embolism, carbon monoxide poisoning, 
clostridial myonecrosis, refractory osteomyelitis, ORN and others (Jamil et al. 2000, 
Coulthard et al. 2003). 
HBO reduces hypoxia within affected tissues, stimulates angiogenesis in 
hypovascular tissues and improves fibroblastic cellular density. It limits the amount of 
nonviable tissue to be surgically removed, enhances wound healing and prepares 
tissues for reconstruction (Shaha et al. 1997, Grime & Bryson 2001). The mechanism 
of action of HBO has been shown to enhance phagocytic ability of leucocytes (Hunt 
& Pai 1972), stimulate fibroblast growth, increase collagen formation and promote 
growth of new capillaries (Knighton et al. 1981). It is also inhibitory to aerobic and 
anaerobic bacteria and bacterial toxin formation (Mader et al. 1980).  
Clinically it is used to treat various forms of chronic radiation tissue injury producing 
a favorable response in terms of relief of pain, elimination of extraoral sinus tracts, 
return of osseous union in areas of pathologic fractures, and rapid dissolution of 
sequestra without suppuration, so that further loss of hard and soft tissues is kept to a 
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minimum (Mainous & Boyne 1974). It supports wound flaps and grafts placed into 
irradiated tissue to improve function and relieve pain (Myers & Marx 1990, Steckeler 
et al. 1994). HBO therapy represents a more conservative approach in management of 
ORN and enhances the probability of total rehabilitation (Mainous & Boyne 1974). 
Numerous authors recommend the use of HBO prior to surgical therapy for ORN. It 
may also be used prophylactically in patients who require dental extractions and are at 
high risk for developing ORN (David et al. 2001).  
HBO is delivered by sessions within a hyperbaric chamber, which may range from a 
small monoplace chamber for one patient to a multiplace chamber which holds 
several patients and an attendant. A single HBO session for ORN treatment 
commonly consists of patient breathing 100 per cent pure oxygen at 2-2.4 
atmospheres for 90-120 minutes. Usually treatments occur on a daily basis, five to six 
days per week, until the required number of sessions is completed (Davis et al. 1979, 
Vudiniabola et al. 1999). The guideline used for dental extractions after RT usually 
consists of 20-30 sessions before the procedure and 10 after tooth removal (Marx et 
al. 1985, Dhanda et al. 2009). At least 20 to 30 mm Hg of wound PO2 is needed to 
increase oxygen to hypoxic tissues (Davis et al. 1979). 30 dives of HBO result in a 
mean increment of 50-86 % of transmucosal oxygen in hypoxic tissues (Thorn et al. 
1997). Other protocols are also designed for irradiated patients requiring implant 
treatment (Granström et al. 1993). Patients receiving more than 60 Gy and in need for 
extraction of mandibular teeth within the irradiated field appear to benefit most (Nabil 
& Samman 2011). 
Toxic effects are usually observed in central nervous system (Koga et al. 2008a) and 
main contraindications against employment of HBO are some drugs, non-treated 
pneumothorax, neuritis, some forms of pulmonary disease, smoker’s emphysema, 
active viral infections (Giebfried et al. 1986, Vudiniabola et al. 2000, Chavez & 
Adkinson 2001), as well as some certain chemotherapeutic agents like bleomycin, 
cispatin and adriamycin (Vanderpuye & Goldson 2000). The only absolute contra-
indications to HBO are optic neuritis, and existing neoplasia (Wood & Liggins 1996). 
Although HBO may stimulate malignant growth (Feldmeir 2004), it is not 
contraindicated in patients with treated neoplasia (Marx & Ames 1982). HBO may be 
of use pre- and postoperatively in patients with neoplasia both in primary and delayed 
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reconstruction cases. Side effects of HBO are uncommon but include transient myopia 
(Kaur et al. 2009), seizures, and otic or pulmonary barotraumas, the latter potentially 
leading to air embolism (Vudiniabola et al. 1999, Chavez & Adkinson 2001, 
Bessereau & Annane 2010). Concern has been expressed that HBO may exacerbate a 
variety of autoimmune and immunosuppressive disorders, and viremia (Giebfried et 
al. 1986), but there is little supporting evidence. Relative contraindications to HBO 
therapy include upper respiratory tract infection, chronic sinusitis, epilepsy, chronic 
obstructive airways disease, high fevers, a history of spontaneous pneumothorax or 
thoracic or ear surgery, arterial air embolism, oxygen toxicity seizure, pulmonary 
oxygen toxicity, acute pulmonary edema, viral infections, congenital spherocytosis, a 
history of optic neuritis, and claustrophobia (Giebfried et al. 1986, Scully & Epstein 
1996, Leach et al. 1998, London et al. 1998, Vudiniabola et al. 1999). Further 
limitations include limited availability, especially outside main cities and cost of the 
treatment (Vudiniabola et al. 1999). 
Many animal studies (Hamblen 1968, Yablon and Crucss 1968, Wada & Iwa 1970) 
and clinical reports about use of HBO exist until nowadays, yet there is controversy 
about its effectiveness. In 1973, Greenwood & Gilchrist reported for first time the 
benefits of HBO on wound healing in postradiation patients (Greenwood & Gilchrist 
1973). Since then, several authors have reported beneficial effects of HBO in 
management of ORN of jaws. In 1975, Mainous & Hart treated 14 cases of refractory 
mandible ORN with HBO and hemimandibulectomy, with complete resolution of all 
cases (Mainous & Hart 1975). In 1978, Farmer et al. studied the use of HBO and 
found resolution in 54% and improvement in 23% of patients (Farmer et al. 1978). In 
1981, Mansfield et al. treated 12 patients with refractory ORN of mandible with HBO 
therapy, resulting in complete healing in 11 cases (Mansfield et al. 1981). In 1983, 
Marx reported successful resolution in all of 58 cases of ORN using HBO in 
combination with surgery (Marx 1983b) and in 1984 Beumer et al. found HBO 
helpful in treatment of large areas of ORN when combined with surgical 
sequestrectomy (Beumer et al. 1984). McKenzie et al. (1993) published treatment 
with HBO of postradiation ORN of the mandible in 26 patients and concluded that 
resolution occurred in 69% (18 of 26) of the patients, improvement occurred in 12% 
(3 of 26) of the patients but 19% (5 of 26) of the patients did not show any 
improvement. Merkesteyn et al. (1995) reported a combination of surgical 
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debridement, antimicrobial therapy and HBO in 27 patients and concluded that 20 
(69%) had completely healed after this treatment. Epstein et al. (1997) reported the 
results of a long-term follow-up study with the same group of patients previously 
published by McKenzie et al (1993). Of the 20 patients followed, 12 had completely 
healed, improvement had occurred in two patients and five of the patients still had 
chronic persistent ORN. Neovius et al. (1997) reported results on treatment with HBO 
after surgery in irradiated head and neck in 15 consecutive patients and compared 
them with a group of patients treated without HBO. The authors concluded that 12 out 
of 15 patients treated with HBO had healed completely and that only seven of 15 
patients with similar signs of ORN had healed after therapy without HBO. In the 
study of Curi et al. (2000b) complete healing was achieved in 14 of 18 patients who 
were treated with HBO. Similar encouraging results were published by many other 
authors (Hart & Mainous 1976, Cronje 1998, Feldmeier & Hampson 2002, Hampson 
et al. 2012). 
Although benefits of adjunctive HBO therapy in irradiated tissues have been 
demonstrated in a series of reports, some authors do not agree with use of HBO for 
treatment of ORN (Epstein et al. 1987a, Wong et al. 1997). In a retrospective study of 
28 patients with mandibular ORN managed by conservative measures only, Wong et 
al. (1997) showed that 14 patients had complete healing. A previous study (Curi & 
Dib 1997), in which 104 patients with ORN were treated with conservative 
approaches (local debridement/gentle sequestrum removal), supports this statement, 
since it resulted in healing of 42.3% of patients. Reports of several other authors 
indicate that most cases of ORN can be managed successfully without HBO (Daly & 
Drane 1972, Beumer et al. 1984, Marciani & Ownby 1986, Harris 1992, Schwartz & 
Kagan 2002, Annane et al. 2004, Besserau & Annane 2010, Pitak-Arnoop et al. 2010). 
There is also insufficient information to show that use of HBO reduces the incidence 
of ORN in irradiated patients requiring tooth extraction or implant therapy (Schoen et 
al. 2007, Fritz et al. 2010). 
In conclusion, HBO alone cannot heal ORN wounds (Epstein et al. 1987b, Granström 
et al. 1992, Van Merkesteyn et al. 1995). HBO without aggressive surgical 
management would not resolve disease progress in most cases. Only ‘mild’ cases of 
ORN can be cured with HBO, and severe cases will need surgery to remove dead 
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bone (McKenzie et al. 1993, Mounsey et al. 1995). Postoperative HBO cannot be 
treatment of choice if operation fails to treat ORN (Maier et al. 2000). Purpose of 
hyperbaric therapy is to prepare patient for surgical debridement and appropriate 
grafting, not try to rescue poor results following inappropriate use of surgery in the 
treatment of ORN (Grime & Bryson 2001). Finally, there is need for greater quality 
research into the value of HBO for prevention of ORN (Shaw & Butterworth 2011); 
there is also a need for randomized controlled clinical trials to determine effectiveness 
of HBO in irradiated patients who require dental extractions or implant therapy 
(Coulthard et al. 2003). 
8.1.2 Ultrasound therapy 
Ultrasound therapy is a conservative alternative therapy to HBO. Ultrasound increases 
angiogenesis and stimulates collagen and production of bone (Harris 1992). 
Ultrasound may be valuable in treatment of delayed unions, in callus maturation after 
distraction, and in treatment of ORN (Schortinghuis et al. 2003). According to a study 
conducted by Harris (1992), a regimen of ultrasound with local debridement and 
metronidazole has proved to be an effective and practicable treatment for ORN, 
achieving healing in ten out of 21 cases (48 %) without surgery. He also proposed a 
protocol for ultrasound in treatment of ORN. This includes 40–50 sessions of 10 min 
each until healing is complete. 
8.2 Surgical treatment 
Surgery is recommended in cases of extensive ORN with intractable pain, severe 
trismus, multiple discharging fistulae, a large area of exposed necrotic bone, or a 
coexistent fracture (Zarem & Carr 1983, Koka et al. 1990, Shaha et al. 1997, Hao et 
al. 1999, Maier et al. 2000). In cases of no response to conservative treatments 
intensive care is usually required for a long period, and sometimes the result is 
progressive destruction and pathologic mandibular fracture. In these cases, radical 
resection of mandible is needed (Guttenberg 1974, Marx 1983b, Beumer et al. 1984, 
Nakatsuka et al. 1996, Shaha et al. 1997, Aitasalo et al. 1998, Oh et al. 2009). Until 
inception of intraoral approach to mandibular resection for ORN, extraoral route had 
been utilized with a great degree of morbidity and mortality (Marchetta et al. 1967). 
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Surgical therapy of ORN includes removal of small sequestra, radical sequestrectomy 
alveolectomy with primary closure or hemimandibulectomy, closure of orocutaneous 
fistulae and local or microvascular free flap reconstruction (Chrcanovic et al. 2010b). 
Immediate reconstruction using a fibular free graft, scapular osteocutaneous flap, a 
free serratus anterior/rib flap or vascularized iliac crest flap provides excellent 
functional and cosmetic results (Ioannides et al. 1994, Nakatsuka et al. 1996, Chang et 
al. 2001). Promising results have also been observed with free omental transfer 
(Kobayashi et al. 2000). 
In his study Oh et al. (2009) concluded that radical resection of necrotic and infected 
bone is the most valuable treatment in terms of successful outcome of therapy. 
Criteria for determining the extent of mandible resection involve a preoperative 
estimation with a CT or MRI and intraoperative assessment of bone vascularity by 
examining for presence of osseous bleeding from margins of resection (Buchbinder & 
Hilaire 2006, Curi et al. 2007, Suh et al. 2010). Newer techniques include 
measurement of partial pressure of oxygen (PO2) with Eppendorf fine needle probe 
(Meuer and Meyer 2006) and intraoperative tetracycline bone fluorescence (Pautke et 
al. 2010). Simply resecting grossly necrotic bone does not ensure curability of ORN, 
and further studies are needed to prevent ORN and its morbidity. However, until 
nowadays there is no better approach in assessing resection margins. It can be argued 
that a more aggressive surgical approach including a hemimandibulectomy plus 
condylectomy in unilateral ORN cases and near-total mandibulectomy in bilaterally 
affected mandibles may be the only way to minimize recurrence. However, this more 
aggressive approach may produce unforeseen morbidities in speech and swallowing 
function (Zaghi et al. 2012). 
The concept of wide radical resection of affected bone with immediate reconstruction 
has gained wide acceptance in the literature and seems therapy of choice in advanced 
ORN of the jaws especially in mandible (Curi & Dib 1997, Shaha et al. 1997, Celik et 
al. 2002, Schwartz & Kagan 2002, Wei et al. 2003, Curi et al. 2007, Hirsch et al. 
2008, Oh et al. 2009). Many authors reported a positive effect on the quality of life of 
these patients regarding reduction in pain and improvement of form and function 
(Koka et al. 1990, Curi and Dib 1997, Celik et al. 2002, Curi et al. 2007). 
Reconstruction of resected mandible needs to be performed using a nonirradiated flap. 
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This will provide an improved blood supply to the region, promoting healing and 
perhaps enhancing viability of the remaining bone that might be marginally involved 
with ORN (Baker 1983).  
Soft tissue reconstruction alone, either as a pedicled or free flap, can be performed. 
These procedures have the disadvantage that they require secondary bone grafting to 
obtain bony restoration (Baker 1983, Nakatsuka et al. 1996). Although fibular free 
flap is described as a very safe and reliable option for reconstruction, failure and 
complication rate varies between 8.7 and 20 % (Chang et al. 2001, Curi et al. 2007, 
Hirsch et al. 2008, Mücke et al. 2013) flap loss, and 21–43 % (Gal et al. 2003, Hirsch 
et al. 2008) overall complications. In classes 2 and 3 of ORN, the use of 
microvascular free flaps provides safe results with a high quality outcome of 
reconstruction (Curi and Dib 1997, Shaha et al. 1997, Celik et al. 2002, Schwartz & 
Kagan 2002, Curi et al. 2007, Hirsch et al. 2008, Wei et al. 2003). 
The optimal reconstruction, particularly for a long segment of bone, is a vascularized 
composite flap, such as fibular, scapular, iliac crest, or radius bone (Nakatsuka et al. 
1996, Shaha et al. 1997). Mandibular reconstruction with a fibula flap is an elegant 
solution to restore anatomic arch, oral functions and facial esthetics (Bodard et al. 
2011). Although the use of bony flaps like free fibular or iliac crest flaps is perfect for 
full rehabilitation, these are more demanding procedures and may not be as successful 
as soft tissue only flaps (Mücke et al. 2013). In contrast, local wound closure after 
wound debridement, demonstrates a high rate of failure (Mücke et al. 2013).  
In general, patients with adequate soft tissue volume and quality (limited fibrosis 
without contraction where proper wound closure and coverage of the plate can be 
achieved) can be resected transorally and stabilized with a reconstruction plate. Those 
with a quantitative soft tissue deficiency should be resected through a MacFee-type 
neck incision, and reconstructed with an immediate soft tissue myocutaneous flap like 
pectoralis major (Marx & Morales 1998), lattisimus dorsi, trapezius and 
sternocleidomastoid, which permits stabilization of bony segments with a 
reconstruction plate. Bony reconstruction (stage III-R) should be accomplished after 
about 3 months, with particulate bone and cancellous marrow graft harvested from 
posterior ilium or other part of the body (Peleg & Lopez 2006). 
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8.3 New treatment techniques 
Recently, some authors propose the possibility of bone regeneration with use of 
platelets rich plasma (PRP) with promising results (Tözüm & Demiralp 2003, 
Boyapati & Wang 2006, Mannai 2006, Roukis et al. 2006, Rutkowski et al. 2007, 
Scala et al. 2007). PRP is the portion of blood containing the concentrate of platelets 
which are rich in mitogenic growth factors (GFs) such as platelet derived growth 
factors (PDGFs), transforming growth factor beta TGF-β, epidermal growth factor 
EGF, insulin like growth factor IGF and vascular endothelial growth factor VEGF. 
Growth factors entrapped within alpha granules in platelets corpuscles are released 
upon a process called ‘platelets activation’ that consists of bursting granules to release 
their GFs content. This occurs primarily by thrombin. Within their environment of 
release, such GFs play a crucial role in orchestrating the molecular cascade of healing. 
Benefit of the introduction of such a GF into a healing lesion might be emphasized 
especially in critical-size defects. A therapeutic advantage of PRP in this type of 
defect is introduction of the ‘right’ concentrated GFs that are missing for the healing 
process and their introduction in natural proportions necessary for a proper interaction 
to stimulate different pathways that ultimately lead to activation of gene expression 
and production of necessary proteins for healing (Kassolis et al. 2000, Van den Dolder 
et al. 2006). Use of PRP may reduce or eliminate the need for invasive procedures 
such as resection and reconstruction of mandible (Scala et al. 2010). However, it 
failed in some studies to show beneficial results (Batstone et al. 2012). 
A new therapy focuses on the use of pentoxifylline and antioxidant alpha-tocopherol 
(vitamin E) pentoxyfiline (PENTO) (Kahenasa et al. 2012). PENTO was reported to 
be successful in healing superficial cases of radiation induced fibrosis, but was found 
to be insufficient for use alone in long standing ORN (Kahenasa et al. 2012). Delanian 
et al. (2005 & 2011) found that combination of Clodronate and PENTO was 
beneficial in severe cases of radiation induced fibroatrophic process inducing 
mandibular ORN but clodronate carries a potential risk of bisphosphonate-related 
osteonecrosis. All patients with a need of dental extractions could be given eight 
weeks of pentoxyfiline 400 mg twice daily with tocopherol 1.000 IU, starting a week 
before the procedure. If ORN developed, then they could be continued for a further 
six months with clodronate prescribed after three months if there has been no 
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appreciable response (Lyons & Ghazali 2008). Nevertheless, further controlled and 
randomized clinical trials are necessary in order to confirm the effectiveness of 
PENTO regimen in treatment of ORN (Kahenasa et al. 2012). 
  
 
 
 
Chapter 9 
 
Prevention of osteoradionecrosis 
Improvements in RT that were mentioned above (3D-CRT, IMRT) aim to prevent 
complications after RT, especially ORN. In addition to these attempts a thorough, 
early pre-irradiation dental assessment and a dental care programme are also steps to 
this direction (Carl et al. 1972, Regezi et al. 1976, Makkonen et al. 1987, Kluth et al. 
1988, Scully & Epstein 1996, Vudiniabola et al. 1999, Wahl 2006, Monnier et al. 
2011). The aim is to identify the main factors that will likely increase the risk for 
ORN and take steps in order to control or eliminate as many factors as possible before 
RT begins (Stevenson- Moore 1990, Jansma et al. 1992b, Thorn et al. 2000, Schiodt 
& Hermund 2002). Primary goal should be to optimize the condition of patient's 
dentition, so that high risk procedures like extraction of teeth, apicoectomies, etc., will 
not have to be performed in the post-irradiation period (Beumer & Brady 1978, 
Beumer et al. 1979a, Beumer et al. 1979b, Stevenson-Moore 1990, Jansma et al. 
1992b, Curi & Dib 1997, Tong et al. 1999, Thorn et al. 2000). An adequate time for 
treatment and healing must also be allowed before the onset of RT (Vanderpuye & 
Goldson 2000, Shaw & Butterworth 2011). 
A trained dentist should evaluate the condition of teeth and associated tissues and 
should conduct a complete dental, oral and pharyngeal examination (Hayward et al. 
1969, Coffin 1983). Necessary treatment should be administered at once so that RT 
will not be delayed unreasonably. During preirradiation period, the patient should 
receive restorative and periodontal therapy which is necessary and should be taught 
oral hygiene. Oral cavity should be examined and pressure points from removable 
dentures should be eliminated (Hellstein & Marek 2006). The decision to extract teeth 
or not must be left to a skilled oral surgeon who can evaluate each patient individually 
(Coffin 1983, Makkonen et al. 1987).  
Whether to extract teeth before RT or not has been a thema of great controversy 
(Degnan 1964). Several factors such as individual characteristics of patients, tumor 
and oncological treatment and dental factors should be considered in order to take the 
  
 
 
74 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 9 
 
decision of performing preradiation extractions (Koga et al.2008a, Shaw & 
Butterworth 2011). Knowledge of radiation dose, modality of treatment, field of 
radiation, and tumor prognosis combined play an important role in clinical decision-
making. Consideration is also given to preexisting periodontal condition of tooth or 
teeth in question and motivation of patient to follow a strict programme of oral 
hygiene (Murray et al. 1980c, Reuther et al. 2003, Sulaiman et al. 2003). 
Results of published papers are controversial. Daland (1949) rendered the patient 
edentulous and so did Watson and Scarborough (1938) before the days of antibiotics. 
Some researchers have suggested that all teeth in the path of radiation should be 
removed (Del Regato 1939, Niebel & Neeman 1957, Robinson 1964). MacComb 
(1962) and Cook (1966) expressed the opinion that all teeth which would require 
extraction for dental reasons within one year after radiation should be extracted prior 
to irradiation. Other authors have reported that dental extractions which are associated 
with RT result in minimal complications (Wildermuth & Cantril 1953, Solomon et al. 
1968). A very conservative attitude toward extractions was proposed by Paterson 
(1963), who advised that most teeth should be retained in spite of inevitable 
complications. Daly and Drane (1972) expressed the opinion that only teeth which are 
completely unsalvageable and would require extraction shortly after treatment, and 
those that would be the source of severe post irradiation complications if left in place, 
should be removed. Daly (1977) mentioned that extraction of totally decayed or 
periodontally involved teeth should be considered only if an adequate healing time 
(seven to ten days) was available. According to Beumer et al. (1984) all teeth with a 
questionable prognosis should be extracted. They also mentioned that dentition with 
significant periodontal deficiencies is difficult to maintain, and is quite susceptible to 
caries as well as periodontal infections after RT. Bruins et al. (1998) suggested a 
complex tooth-by-tooth algorithmus of extraction of teeth. Another school of thought 
proposes conservation of as many functional teeth as possible for the patient, provided 
that a continuous preventive, restorative and periodontal care is available (Tong et al. 
1999). 
Nowadays, extraction of teeth prior to RT is recommended for teeth with poor 
condition or poor prognosis (MacComb 1962, Morrish et al. 1981, Stevenson-Moore 
1990, Jansma et al. 1992b, Thorn et al. 2000, Schiødt & Hermund, 2002, Koga et al. 
  
 
 
75 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 9 
 
2008a). Although in some cases a conservative approach is indicated, the less 
motivated the patient, the more aggressive one should be in extracting teeth before RT 
(Beumer et al. 1979a, Beumer et al. 1979b, Horiot et al. 1981, Jansma et al. 1992b, 
Epstein et al. 1999b, Epstein & Stevenson-Moore 2001). Teeth that are located in the 
high-dose radiation field should be extracted before RT if they are nonrestorable 
(Epstein 2001). Teeth that are likely to be nonfunctional or inaccessible after other 
extractions or due to cancer treatment effects should also be removed (Shaw & 
Butterworth 2011). Criteria for extraction of teeth before RT include moderate to 
advanced periodontal disease, periodontal pockets over 5-6mm (Schiodt & Hermund 
2002), furcation involvement of grade 2 and mobility of grade 2 or more, extensive 
periapical root lesions, extensive decays, partially impacted teeth, and residual root 
tips not fully covered by bone (Murray et al. 1980a, Beumer et al. 1984, Jansma et al. 
1992b, Sulaiman et al. 2003, Vissink et al. 2003a). Fully embedded teeth may not 
require removal if they are otherwise normal (Rothwell 1987, Mealey et al. 1994, Oh 
et al. 2004), but if they can provide an infectious pathway to the jaw bone and other 
problems they have to be extracted (Hayward et al. 1969). An indiscriminate 
extraction of all teeth is not idicated. Extractions of unrestorable, but asymptomatic 
teeth in pre-radiation visits or in the post-radiation period in patients with advanced or 
end-stage diseases are not advocated (Koga et al. 2008b). A minimum of 2 weeks 
should be allowed prior to onset of RT (Hayward et al. 1969, Epstein et al. 1987a, 
Marx & Johnson 1987, Berger et al. 1998) although there are studies where ORN 
developed 3 years after extraction of teeth (Chang et al. 2007). 
The next phase of prevention of ORN includes the intrairradiation and postirradiation 
period. During this phase the patient’s oral and dental health should not be 
overlooked. Patients should be followed up at regular intervals throughout their 
lifetime as septic ORN can occur at any time after RT. At each examination it must be 
determined whether there is a recurrent or new tumor or any degenerative change of 
teeth, bone, or oral soft tissue. Scaling measurement of the periodontal pocket depth 
and plaque index should be conducted once every 6 months and radiograph 
examination once every 12 months (Katsura et al. 2008). Acute dental diseases can be 
managed either with endodontic therapy or extraction of the affected teeth. This 
decision should be made on an individual basis depending upon patient‘s general 
condition and severity of dental problem (Guttenberg 1974). Dental extractions should 
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be delayed 9-12 months after completion of RT in order to reduce the risk of ORN 
(Vanderpuye & Goldson 2000). Postirradiation biopsies should also be avoided since 
trauma and secondary infection may lead to true necrosis (Howland et al. 1975). 
In case of extractions most authors suggest that they should be performed with 
minimal trauma or atraumatically to reduce risk of developing ORN (Solomon et al. 
1968, Kraut 1985, Epstein et al. 1987b, Schweiger 1987, Maxymiw et al. 1991, Tong 
et al. 1999, Lye et al. 2007, Kaur et al. 2009, Sulaiman et al. 2003). Atraumatic 
extraction is best described as limited mucoperiosteal disruption (Beumer et al. 1979b, 
Marciani & Ownby 1986, Maxymiw et al. 1991) and minimal bone injury. This can 
not be possible in difficult cases due to tooth-root morphology, impaction or deeply 
retained roots. The logic is to preserve integrity of periosteum, an important source of 
vascularity especially in impaired tissues (Beumer et al. 1979b). Alveoloplasty and 
suturing of socket are commonly performed to avoid ORN (Solomon et al. 1968, 
Rankow & Weissman 1971, Beumer et al. 1983b, Marx et al. 1985, Epstein et al. 
1987b, Lambert et al. 1997, Carl & Ikner 1998, Tong et al. 1999, Chaux-Bodard et al. 
2004, Lye et al. 2007). This procedure attempts to trim off sharp bony spicules and 
provide soft tissue coverage for the sockets to prevent bone exposure (Daly & Drane 
1972, Bedwinek et al. 1976, Starcke & Shannon 1977). Niebel and Neeman (1957) 
suggested that alveoloplasty should be done to reduce clot size. Another reason is that 
alveolar ridge will not readily remodel in this compromised tissue resulting in an 
irregular ridge that would cause increased risk of bony exposure when wearing a 
denture in the future (Carl et al. 1973, Beumer & Frady 1978). Limiting the number of 
teeth extracted per session has been suggested to prevent ORN by avoiding 
overburdening the already limited blood supply (Carl et al. 1973, Beumer et al. 1983b, 
Maxymiw et al. 1991). Other less popular suggestions include avoiding lidocaine or 
adrenaline-containing local anesthesia (Maxymiw et al. 1991, Chaux-Bodard et al. 
2004, Lye et al. 2007), use of a nasogastric tube during postoperative period (Horiot et 
al. 1983), elastic or orthodontic extraction (Niebel & Neeman 1957) and 
chlorhexidine mouthwash (Tong et al. 1999, Lye et al. 2007). Antibiotic prophylaxis 
is also part of preoperative preparation before extraction in irradiated population 
(Daly et al. 1972, Coffin 1983, Epstein et al. 1987b, Makkonen et al. 1987, Maxymiw 
et al. 1991, Costantino et al. 1995, Tobias & Thomas 1996, Tong et al. 1999, Kanatas 
et al. 2002, Sulaiman et al. 2003, Lyons & Ghazali 2008) since the incidence for post-
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extraction ORN with use of antibiotics is 6% (Beumer & Seto 1981, Beumer et al. 
1983a, Beumer et al. 1983b, Nabil & Samman 2011). Alternatives to tooth extraction 
for patients who have been irradiated to the jaws are treatment of infected teeth roots 
and grist to the level of gingiva (Hayward et al. 1969, Beumer & Seto 1981, Beumer 
et al. 1984) as well as exfoliation of hypermobile teeth (Hayward et al. 1969). 
Attention should also be paid to dental care with efforts to ensure that caries is 
continuously and effectively prevented (Hayward et al. 1969, Daly & Drane 1972, 
Beumer et al. 1979b, Makkonen et al. 1987, Jolly 2004). In order to prevent 
occurrence of radiation caries, topical sodium fluoride gel should be applied daily to 
the remaining teeth for an indefinite period (Curi & Dib 1997, Jolly 2004, Chang et al. 
2007). This procedure can be performed by the patient himself using a custom-made 
fluoride gel carrier. Application of 1% fluoride gel showed reduction in incidence of 
ORN from 35% to 24.5 % (Daly et al. 1972). A prospective French study showed also 
no case of post-dental extraction ORN in patients adhering to post–irradiation 
programme including five minutes daily application of fluoride gel and use of fluoride 
toothpaste (Horiot et al. 1983). As radiation-induced xerostomia is a causative factor 
of dental caries (Moller et al. 2004) and ORN, maintenance of a moist oral 
environment is crucial to prevent ORN (Jolly 2004). Patient with a dry mouth should 
avoid anything that further impairs salivation like drugs, tobacco and alcohol. They 
may benefit from dietary control, taking frequent sips of water and using artificial 
saliva (Scully & Porter 2001). 
Patient’s compliance plays also an important role in the prevention of ORN (Horiot et 
al. 1983, Perrier & Moeller 1994). Besides regular participation in the oral surgical 
and oncoradiological control examinations, patients must devote particular care to the 
cleanliness of teeth and to maintain a healthy parodontium. Minor dental interventions 
with a preserving aim, depurations and periodontal treatments may always be 
performed without delay, since unrestorable dental caries and moderate to severe 
periodontal disease are risk factors of ORN (Epstein & Stevenson-Moore 2001, 
Schiodt & Hermund 2002). In all cases it is recommended to learn the opinion of the 
treating physician in advance. Use of a chlorhexidine-containing toothpaste and oral 
rinse can ensure effective defence against plaque formation and secondary periodontal 
diseases, which may play a decisive role in superinfection of bone which is in a 
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damaged condition following irradiation (Calman 1991). In the event of complaints 
patients must turn immediately to the treating physician (Nemeth et al. 2000). 
All the above mentioned measures can reduce likelihood of ORN by a factor of 3 
(Grötz et al. 2001b). It can be concluded that it is important to prevent intraosseous 
infection by consistent pretherapeutic dental hygiene (Bast et al. 2013). This can be 
achieved by thorough explanations to patients for the importance of dental 
management and a “close follow-up” schedule (Jacobson et al. 2010). 
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Purpose of the study 
Until nowadays, a great number of authors have studied the entity of ORN and risk 
factors for its occurrence. Several staging systems have been proposed to aid 
management of ORN. There exists also a wide spectrum of clinical and radiological 
manifestations of ORN. However, its treatment remains challenging despite multiple 
options proposed through the years.  
A search of the literature (PubMed and MEDLINE Database, Cochrane Library) 
revealed a distinct lack of studies that identify factors associated specifically with the 
severity of mandibular ORN. The investigation of the severity is clinically extremely 
important, since the management of the severe cases differs considerably from that of 
early-stage disease. Clinical symptoms, radiological findings and prophylaxis 
protocols present a wide variance among the different stages of necrosis.  
For these reasons, the purpose of this study is to find risk factors indicating the 
severity of ORN. More specifically it aims to: 
i. describe the demographic data of patients that were treated for ORN, 
ii. examine the tumor characteristics of these patients, 
iii. investigate the oral status and symptomatology of these patients, 
iv. detect factors that may have contributed to the onset of necrosis, 
v. examine the frequency of areas where necrosis occurred, 
vi. record the treatment methods of patients, 
vii. identify risk factors associated with the severity of ORN and finally, 
viii. delineate and correlate these factors with the general characteristics of the 
patients 
The establishment of these factors would help to formulate appropriately aggressive 
prophylaxis and treatment strategies based on the severity of occurrence of ORN. 
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Material and methods 
A retrospective analysis of 115 patients who were diagnosed with ORN and were 
treated in the Department of Oral and Maxillofacial Surgery in Munich (LMU) in the 
period from January 2003 until December 2012 was conducted. These patients 
suffered from ORN once or more times during their life, either at the same or different 
areas from the initial outbreak. The study was approved by the Ethical Committee of 
the University of Munich (Project-Nr. 083-11). 
ORN of the jaws was defined as exposed irradiated bone that fails to heal over a 
period of 3 months without evidence of persisting or recurrent tumor (Marx 1983a, 
Marx & Johnson 1987, London et al. 1998, Teng & Futran 2005, Pitak- Arnnop et al. 
2008, Khojastepour et al. 2013). 
Taking into account this definition inclusion criteria were the following: 
• patients with head and neck tumors who had been treated with RT once or 
more times in their life, 
• patients with denuded bone in the oral cavity for a period of more than 3 
months, 
• patients with no evidence of persisting or recurrent tumor, 
• patients with no use of antiresorptive drugs (bisphosphonates or denosumab) 
before, during or after tumor therapy, 
• patients with histologically proven ORN 
Data were gathered by searching medical records of the patients, including files, 
letters, radiographic findings, histological examinations, photographs and operational 
reports. Data that were collected included: 
1. personal data (age, gender), 
2. health data (general health problems, smoking, alcohol consumption), 
3. tumor data (localization, staging, means of therapy, dose of radiation, times of 
radiation), 
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4. oral health data (dental treatment before RT, dental treatment during or after 
RT) 
5. information about symptomatology and factors that contributed to the onset of 
ORN 
6. information about the methods of treatment conducted to these patients 
7. information about the exact localization of necrosis to the jaws 
All radiological examinations (OPT, CT, MRI) were thoroughly examined not only 
for general pathologic changes but also for abnormalities specific to ORN lesions. 
These included localized osteolytic areas, extensive osteolytic areas, sequestra, 
fractures, persistent sockets after tooth extraction and mixed radio-opaque radiolucent 
lesions.  
Particular emphasis was given to the exact localization of necrosis. Localization was 
recorded after search in the medical files and was compared with data available on 
radiological examinations and photos. Affected regions were numbered according to 
the International Dental Scheme of Fédération Dentaire Internationale (FDI). A 
distinction between localization in maxilla and mandible was also conducted. 
RT was categorized as: RT in head and neck region or RT in other parts of the body; 
metastasis in bone was differentiated from metastasis in other parts of the body. 
Smoking was recorded not only for active smokers at the time of the study conduction 
but also for those who had given the habit up after tumor therapy. The following 
symptoms were documented: exposure of bone, pain, swelling, inflammation, fistula, 
fracture, pus and inferior alveolar nerve hypesthesia. The treatment provided was 
divided into two groups: i) conservative including antibiotics, analgesics, debridement 
and sequestrectomy, and ii) surgical including radical sequestrectomy, alveolectomy 
with primary closure or hemimandibulectomy, closure of orocutaneous fistulae and 
local or microvascular free flap reconstruction. 
Initially, the descriptive assessment of the data was carried out first by calculating 
observed values and relative frequencies over the entire patient population. Then the 
total sample was categorized in three groups (stages) based on the classification of 
Notani et al. (2003) (Table 3). Different variables were evaluated in an attempt to find 
a correlation between them and the severity of necrosis. 
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Table 3. Notani et al. classification of ORN after clinical examination and orthopantogram 
     Stage                                                         Criteria 
I ORN confined to dentoalveolar bone 
II ORN limited to dentoalveolar bone or mandible above the inferior dental 
canal, or both 
III ORN involving the mandible below the inferior dental canal, or 
pathological fracture, or skin fistula 
        
The variables were analyzed using the Statistical Package for the Social Sciences 
(IBM SPSS Statistics v.22, New York, NY, USA). Data analysis included descriptive 
statistics by analyzing observed values and frequencies. Association between 
categorical variables was tested for statistical significance using the chi-square test. 
The sample was then categorized in two groups. Group 1 consisted of stage III cases 
and group 2 included stage I and II cases. Those variables that demonstrated 
significant associations with the dependent variable ‘stage of necrosis’ were included 
in a binary logistic regression model in order to identify significant predictors for the 
stage III of necrosis. The level of significance was set in all cases at p = 0.05. 
 
 
 
 
 
 
 
  
 
 
 
Chapter 11 
 
Results 
Results were classified in the following categories: data regarding sample size, data 
regarding stage of necrosis, personal characteristics, general health characteristics, 
tumor-related characteristics, treatment-related characteristics, information about the 
oral health of patients and factors that contributed to the onset of ORN, information 
about symptomatology and localization of necrosis, information about treatment of 
necrosis and results of the logistic regression. 
11.1 Data regarding sample size 
One hundred fifteen patients were diagnosed with ORN and were treated in the 
Department of Oral and Maxillofacial Surgery in Munich (LMU) in the period from 
January 2003 until December 2012. From these patients 86 developed ORN once, 23 
twice, 4 patients three times, 1 patient four times and 1 five times. The final sample 
consisted of 153 cases of ORN. Figure 1 shows the number of cases diagnosed in each 
institution. 
Figure1. Percentages (%) of cases being diagnosed in each institution 
 
 
  
 
 
85 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 11 
11.2 Data regarding stage of necrosis 
One hundred percent of patients had mandibular ORN and none of them developed 
ORN of the maxilla. The distribution of cases according to the stage of ORN is shown 
in figure 2. Ninety-nine cases were stage III, followed by 31 stage II cases and 23 
stage I cases. 
Figure 2: Percentages (%) of cases by each stage of necrosis 
                                  
11.3 Personal characteristics 
Personal characteristics are shown in table 4. The mean age of cases at the time of 
occurrence of ORN was 60.68 years (SD=9.3). One hundred seventeen of the cases 
were male and 36 were female. Ninety-one of the cases were dead at the time when 
the study was completed. 
Table 4 shows also the relationship between the variables and severity of necrosis. 
The difference in severity of mandibular ORN was not statistically significant 
between men and women (χ2=1.65, p=0.44) and between the different age groups of 
the cases (χ2=2.33, p=0,675). 
11.4 General health characteristics 
Table 5 shows the general health characteristics of the cases. There was a statistically 
significant association between the severity of ORN and DM (χ2=51.96, p<0.001), 
active smoking (χ2=85.81, p<0.001) and alcohol consumption (χ2=73.71, p<0.001). 
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From the 23 cases that were referred as no smokers, 21 had never smoked and 2 were 
smokers in the past and had given up the habit after tumor diagnosis. The alcohol 
consumption was referred as positive when the patient was drinking more than the 
amount determined from American Heart Association as normal consumption. 
Table 4. Personal characteristics by number (N) and percentages (%) of the cases and their distribution 
into 3 stages. Relationship between categorical variables and stage of necrosis (P-value) 
Demographic factor 
 
N (%) 
Stage I 
N (%) 
Stage II 
N (%) 
Stage III 
N (%) 
P-value* 
Sex  
Male 117 (76.5) 18 (11.8) 21 (13.7) 78 (51.0) 
 0.44 
Female 36 (23.5) 5 (3.3) 10 (6.5) 21 (13.7) 
Age  
≤55 years 36 (23.5) 5 (3.3) 8 (5.2) 23 (15.0) 
0.675 56-65 years 76 (49.7) 14 (9.2) 16 (10.4) 46 (30.1) 
≥66 years 41 (26.8) 4 (2.6) 7 (4.6) 30 (19.6) 
Death  
Alive 62 (40.5) 11 (7.2) 11 (7.2) 40 (26.1)  
Dead 91 (59.5) 12 (7.8) 20 (13.1) 59 (38.6) 
       *Chi-square test 
11.5 Tumor-related characteristics 
Figure 3 presents the initial tumor’s site. Floor of the mouth, tongue and pharynx 
tumor comprised 111 cases of initial tumors. Table 6 outlines the tumor 
characteristics. Tumor size was detected from histological findings and stage was 
estimated according to the UICC system. Tumors were then divided into two groups 
according to their connection with the adjacent tissues (soft and hard tissues) and into 
four groups according to their localization regarding jaws (maxilla, mandible, 
oropharynx, other). A statistically significant association was found between size of 
tumor (χ2=58.58, p<0.001) as well as stage of tumor (χ2=23.54, p=0.001) and severity 
of ORN. There was no significant correlation between tumor connection with soft or 
hard tissues (χ2=0.74, p=0.69) as well as tumor localization (χ2=5.45, p=0.49) and the 
severity of necrosis. 
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Table 5. General health characteristics by number (N) and percentages (%) of the cases and their 
distribution into 3 stages. Relationship between categorical variables and stage of necrosis (P-value) 
General health 
characteristic 
 
N (%) 
Stage I 
N (%) 
Stage II 
N (%) 
Stage III 
N (%) 
P-value* 
Diabetes mellitus (DM)  
Yes 92 (60.1) 0 (0.0) 14 (9.1) 78 (51.0) 
 <0.001 
No 61 (39.9) 23 (15.0) 17 (11.2) 21 (13.7) 
Vessels disease  
Yes 90 (58.8) 14 (9.2) 21 (13.7) 55 (35.9) 
0.47 
No 63 (41.2) 9 (5.9) 10 (6.5) 44 (28.8) 
Rheumatic disorder  
Yes 7 (4.6) 0 (0.0) 1 (0.7) 6 (3.9) 
 0.42 
No 146 (95.4) 23 (15.0) 30 (19.6) 93 (60.8) 
Active Smoking  
Yes 130 (85.0) 5 (3.3) 28 (18.3) 97 (63.4) 
 <0.001 
No 23 (15.0) 18 (11.8) 3 (2.0) 2 (1.2) 
Alcohol  
Yes 117 (76.5) 2 (1.3) 23 (15.0) 92 (60.2) 
 <0.001 
No 36 (23.5) 21 (13.7) 8 (5.2) 7 (4.6) 
*Chi-square test 
Figure 3. Percentages (%) of cases in relation to initial tumor’s site 
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Table 6. Tumor characteristics by number (N) and percentages (%) of the cases and their distribution 
into 3 stages. Relationship between categorical variables and stage of necrosis (P-value) 
Tumor characteristic 
 
N (%) 
Stage I 
N (%) 
Stage II 
N (%) 
Stage III 
N (%) 
P-value* 
Tumor size (T)  
1 24 (15.7) 3 (2.0) 9 (5.9) 12 (7.8) 
<0.001 
2 37 (24.2) 18 (11.8) 6 (3.9) 13 (8.5) 
3 30 (19.6) 0 (0.0) 10 (6.5) 20 (13.1) 
4 62 (40.5) 2 (1.3) 6 (3.9) 54 (35.3) 
Stage (UICC)  
I 20 (13.1) 2 (1.3) 7 (4.6) 11 (7.2) 
0.001 
II 12 (7.8) 4 (2.5) 3 (2.0) 5 (3.3) 
III 39 (25.5) 12 (7.8) 9 (5.9) 18 (11.8) 
IV 82 (53.6) 5 (3.3) 12 (7.8) 65 (42.5) 
Connection with 
tissues 
 
Soft  137 (89.5) 20 (13.1) 29 (19.0) 88 (57.4) 
0.69 
Hard  16 (10.5) 3 (2.0) 2 (1.3) 11 (7.2) 
Localization  
Maxilla 15 (9.8) 2 (1.3) 2 (1.3) 11 (7.2) 
0.49 
Mandible 91 (59.5) 13 (8.5) 17 (11.1) 61 (39.9) 
Oropharynx 41 (26.8) 6 (3.9) 12 (7.8) 23 (15.1) 
Other 6 (3.9) 2 (1.3) 0 (0.0) 4 (2.6) 
*Chi-square test 
11.6 Treatment-related characteristics 
Treatment data of the initial tumor are detailed in table 7. All 153 cases received one 
setting of RT. Among these 10 received also a second setting of RT and 3 received a 
third setting. Data regarding RT dose were available only for 138 cases. The mean 
dose at the first RT setting was 63.4 Gy (SD=6.8) and the mean age at the time of first 
RT setting was 54.5 years (SD=9.1). Eighty point four percent of the cases were 
treated also with chemotherapy and 10 out of 153 cases were treated also with RT in 
other parts of the body. A statistically significant correlation was found between the 
severity of ORN and treatment with chemotherapy (χ2=1.87, p<0.001). There was no 
significant association between severity of ORN and times of RT (χ2=2.14, p=0.71) as 
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well as dose at the first RT setting (χ2=1.64, p=0.44), RT in other parts of the body 
(χ2=0.72, p=0.70) and time between RT and occurrence of ORN (χ2=5.57, p=0.47). 
Table 7. Treatment characteristics of the initial tumor by number (N) and percentages (%) of the cases 
and their distribution into 3 stages. Relationship between categorical variables and stage of necrosis (P-
value) 
Treatment characteristic 
 
N (%) 
Stage I 
N (%) 
Stage II 
N (%) 
Stage III 
N (%) 
P-value* 
RT setting  
First 140 (91.5) 21 (13.7) 27 (17.6) 92 (60.2) 
0.71 First and 1. adjuvant 10 (6.4) 1 (0.7) 3 (2.0) 6 (3.7) 
First and 2. adjuvant 3 (2.1) 1 (0.7) 1 (0.7) 1 (0.7) 
 Dose at first RT setting 
±
  
≤60 Gy 62 (44.9) 10 (7.2) 15 (10.9) 37 (26.8) 
0.44 
>60 Gy 76 (55.1) 12 (8.7) 12 (8.7) 52 (37.7) 
Chemotherapy  
Yes 123 (80.4) 1 (0.7) 26 (17.0) 96 (62.7) 
<0.001 
No 30 (19.6) 22 (14.3) 5 (3.3) 3 (2.0) 
RT in other parts  
Yes 10 (6.5) 1 (0.7) 3 (2.0) 6 (3.8) 
0.72 
No 143 (93.5) 22 (14.4) 28 (18.3) 93 (60.8) 
Time between RT and 
occurrence of ORN 
± 
 
0-3 years 55 (38.7) 12 (8.4) 9 (6.3) 34 (24.0) 
0.47 
3.1-6 years 40 (28.2) 3 (2.1) 10 (7.1) 27 (19.0) 
6.1-9 years 21 (14.8) 2 (1.5) 5 (3.5) 14 (9.8) 
>9 years 26 (18.3) 6 (4.3) 5 (3.5) 15 (10.5) 
*Chi-square test 
 
±Number (N) and percentages (%) have been calculated with respect to the number of cases where data 
was available 
11.7 Oral health condition before radiotherapy and factors that 
contributed to the onset of osteoradionecrosis 
Table 8 shows the data regarding oral health condition of patients before RT and the 
factors that contributed to the onset of ORN. Fifty-six point nine percent of the cases 
did not undergo dental examination and treatment before RT. The difference in 
severity of ORN and dental examination and treatment before RT was statistically 
significant (χ2=33.94, p<0.001).  
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In 59.5% of the cases there was an objective cause for the onset of ORN, whereas in 
40.5% ORN occurred “spontaneously”. The severity of necrosis was correlated with 
the occurrence of ORN either spontaneously or due to a specific factor (χ2=11.99, 
p=0.002). Causes of ORN included many variables such as extraction of a tooth, 
implantation, denture irritation or even a local pathological condition such as marginal 
or apical periodontitis. For better analysis, these variables were divided into two 
groups in the present study. The first group was the dental treatment group including 
extraction, implantation and extraction combined with other dental treatment. The 
second group was the local pathological condition group including denture irritation, 
marginal periodontitis, impacted wisdom tooth and apical periodontitis. Fifty point 
five percent of stage III cases occurred spontaneously, whereas 47.8% of stage I and 
41.9% of stage II were contributed to dental treatment in the region of necrosis (figure 
4). The main cause in the dental treatment group (figure 5) was extraction of a tooth 
(85.6%) but the severity of ORN was not associated with the time of its occurrence 
(χ2=5.20, p=0.52). The main cause in the local pathological condition group (figure 6) 
was marginal periodontitis (82.9%). Factors presented in figures 5 and 6 were also 
statistically significant associated with the severity of ORN (χ2=31.15, p=0.03). 
Table 8. Oral health condition before RT and factors that contributed to the onset of ORN by number 
(N) and percentages (%) of the cases and their distribution into 3 stages. Relationship between 
categorical variables and stage of necrosis (P-value) 
Characteristics 
 
N (%) 
Stage I 
N (%) 
Stage II 
N (%) 
Stage III 
N (%) 
P-value* 
Dental examination & 
treatment before RT 
 
Yes 66 (43.1) 22 (14.3) 15 (9.8) 29 (19.0) 
<0.001 
No 87 (56.9) 1 (0.7) 15 (9.8) 71 (46.4) 
Occurrence of ORN  
Cause 91 (59.5) 19 (12.5) 23 (15.0) 49 (32.0) 
0,002 
Spontaneously 62 (40.5) 4 (2.6) 8 (5.2) 50 (32.7) 
Dental surgery  
No 97 (63.5) 12 (7.8) 18 (11.8) 67 (43.9) 
0.52 
Before RT 10 (6.5) 3 (2.0) 2 (1.3) 5 (3.2) 
After RT 40 (26.1) 8 (5.2) 9 (5.9) 23 (15.0) 
Unknown 6 (3.9) 0 (0.0) 2 (1.3) 4 (2.6) 
*Chi-square test 
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Figure 4. Percentages (%) of cases in relation to the type of occurrence of ORN and their distribution 
into 3 stages 
 
 
 
Figure 5. Percentages (%) of cases in relation to the type of dental treatment* 
 
*Percentages (%) have been calculated with respect to the number of cases which occurred after dental 
treatment 
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Figure 6. Percentages (%) of cases in relation to the type of local pathological condition* 
 
*Percentages (%) have been calculated with respect to the number of cases which occurred due to local 
pathological conditions 
 
11.8 Symptomatology and treatment 
Figure 7 shows the symptoms distributed into three stages. One hundred percent of 
the cases had exposure of bone. In 43.8% of the cases a fracture occurred, and 49.7% 
had a fistula. All of them were stage III cases. The main symptoms in stage II cases 
were inflammation (20.3% of the total), wound healing disorder (20.3% of the total), 
pain (19% of the total) and swelling (18.3% of the total). The majority of stage I cases 
were suffering from wound healing disorder (15% of the total) and pain (5.2% of the 
total). Twenty-one point six percent of the cases presented hypesthesia of the inferior 
alveolar nerve and all of them where stage III cases. 
Treatment methods regarding stage of necrosis are presented in figure 8. Ninety-two 
point two percent of the cases independent of stage were treated surgical. 
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Figure 7. Percentages (%) of cases suffering from each symptom and their distribution into 3 stages 
 
Figure 8. Number (Ν) of cases which have been treated by surgical and conservative treatment or both 
in each stage of osteonecrosis (Ia, Ib, Ic) and in all cases independent of stage (II). Percentage (%) of 
cases which have been treated by each method 
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11.9 Localization of necrosis 
Figure 9 shows a detailed depiction of the areas of teeth that were affected. Affected 
regions were numbered according to the International Dental Scheme of FDI. One 
hundred percent of the cases occurred in the mandible and none of them in the 
maxilla. In 42.5% of cases right side (4.quadrant) of mandible was affected, in 35.9% 
left side (3. quadrant) and in 21.6% both sides. The distribution of cases into posterior 
and anterior region of mouth is shown in figure 10. Seventy-six point five percent of 
the cases occurred in the posterior region, 5.2% in the anterior and in 18.3% of the 
cases both posterior and anterior region were affected. However, there was no 
significant association between the severity of ORN and its localization in anterior or 
posterior region (χ2=2.96, p=5.7).  
Figure 9. Percentages (%) of the affected regions of the mouth according to the International Dental Scheme 
of FDI* 
 
 
*Percentages (%) have been calculated with respect to the total number of times each region was 
affected 
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Figure 10. Percentages (%) of cases localized into anterior and posterior region of the jaws as well as 
upper and lower jaw 
 
11.10 Results of the logistic regression 
The forward stepwise logistic regression analysis revealed the following results: 
• The cases that were suffering from DM were 4.955 times more likely (OR: 
4.955, 95% Cl: 1.965-12.495) to develop stage III necrosis compared to those 
who were not suffering from the disease. 
• The cases that were smoking were 13.542 times more likely (OR: 13.542, 95% 
Cl: 2.085-87.947) to develop stage III necrosis compared to those who were 
not smoking. 
• The cases that were consuming more alcohol than the maximum permissible 
limit were 5.428 times more likely (OR: 5.428, 95% Cl: 1.622-18.171) to 
develop stage III necrosis compared to those who were not drinking. 
• The cases in which ORN occurred spontaneously were less likely (OR: 0.237, 
95% Cl: 0.086-0.655) to develop stage III necrosis compared to those in which 
ORN occurred due to dental treatment or local pathological condition (Table 
9). 
  
 
 
96 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 11 
 
Table 9. Significant predictors for stage III of necrosis. Results of the forward stepwise logistic 
regression analysis* 
Significant predictors B (SE) Exp (B) 
95% Confidence 
level 
P-value 
DM 1.600 4.955 1.965-12.495 0.001 
Smoking 2.606 13.542 2.085-87.947 0.006 
Alcohol 1.692 5.428 1.622-18.171 0.006 
Spontaneous ORN -1.438 0.237 0.086-0.655 0.005 
Constant -2.919 0.054  0.004 
*Variables that were inserted in the logistic regression analysis: 1. Stage of the tumor (UICC) (0: Stage 
I, 1: Stage II, 2: Stage III, 3: Stage 4), 2. DM (0: No, 1: Yes), 3. Active smoking (0: No, 1: Yes), 4. 
Alcohol consumption (0: No, 1: Yes), 5. Concomitant chemotherapy (0: No, 1: Yes), 6. Dental 
examination and treatment before RT (0: No, 1: Yes), 7. Occurrence of ORN (0: spontaneously, 1: due 
to dental treatment/ local pathological condition) 
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Discussion 
Several studies have already investigated the entity of ORN. The majority of them 
have addressed risk factors associated with causation of ORN (Morrish et al. 1981, 
Kluth et al. 1988, Jereczek-Fossa & Orecchia 2002, Reuther et al. 2003, Studer et al. 
2006, Ben-David et al. 2007, Ahmed et al. 2009, Peterson et al. 2010, Gomez et al. 
2011, Bhide et al. 2012, Niewald et al. 2013, Tsai et al. 2013). Only four studies were 
found regarding the severity of ORN (Store & Boysen 2000, Notani et al. 2003, 
Chopra et al. 2011, Gevorgyan et al. 2013). They either consisted of a small sample 
size (Gevorgyan et al. 2013) or focused on the severity of ORN proposing new 
classification systems or modalities of therapy (Store & Boysen 2000, Notani et al. 
2003). Only Chopra et al. (2011) attempted to deal specifically with factors linked 
with disease severity. 
The present study attempted to thoroughly investigate risk factors related to the 
severity of ORN. Its sample size (153 cases) is much higher compared to sample sizes 
from other similar studies (Chopra et al. 2011, Gevorgyan et al. 2013). Data was 
gathered through records of cases of ORN treated in the Department of Oral and 
Maxillofacial Surgery in Munich (LMU). Consequently, its reliance depended on 
accuracy of written record or recall of individuals (recall bias). Sometimes important 
data was either not available (dose of radiation, time between radiation and 
occurrence of ORN) or it was impossible to access important information due to 
restrictions by statute or institutional regulations. The lack of control group made the 
identification of differences in characteristics between patients who suffered from 
osteonecrosis and those who did not impossible, although both were exposed to 
radiation (Hess 2004). 
In this study it was also impossible to conduct a multinomial logistic regression 
(MNL model) in order to identify significant predictors for each stage of necrosis. The 
reason is that a lot of warnings occurred and consequently the validity of the model 
was uncertain. For this reason, the sample was categorized as group 1: stage III cases 
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and group 2: stage I/II cases. A logistic regression was conducted in order to identify 
significant predictors for stage III of necrosis. This classification seems to be more 
appropriate because of the more aggressive management of the advanced disease. 
On the other hand, advantages of the study include low cost and a high amount of 
information available for analysis at the time study was conducted. It was also 
feasible to study the occurrence of ORN without time cost although there is a long 
latency between exposure and disease in the case of ORN. Moreover, the results of 
this study can generate a hypothesis that can be tested in future prospectively with 
better results and improvements in quality of the study (Hess 2004). 
12.1 Data regarding stage of necrosis 
The majority of previous studies used the system of Marx in order to divide patients 
into stages (Marx 1983a). The staging system of Marx is based on use and response to 
HBO therapy which is not widely used as conservative therapy in the Department of 
Oral and Maxillofacial Surgery in Munich (LMU). The staging system of Epstein et 
al. (1987a) is also often used but is focused on the presence or absence of a pathologic 
fracture (Schwartz & Kagan 2002). Due to these limitations the staging system of 
Notani et al. (2003) was used in the present study. This staging system was chosen for 
multiple other reasons as well. It is based on the presence or absence of clinical and 
radiological signs, as opposed to other systems that are nonspecific with regard to site 
of involvement, and are based, at least in part, on patients’ subjective interpretation. 
The classification is also based on pretreatment evaluation and not on treatment 
response or refractoriness, allowing for more accurate categorization. It is also simple 
and memorable. 
In the present study the majority of cases were stage III (64.7%) followed by stage II 
(20.2%) and stage I (15.1%). This finding is in accordance with the published 
literature regarding the severity of ORN. In the study of Gevorgyan et al. (2013) 
64.3% of patients were stage II and III, in the study of Notani et al. (2003) 85 out of 
87 patients were diagnosed with stage II and III disease and in the study of Chopra et 
al. (2011) 89.0% of patients were suffering from stage II and III necrosis. 
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12.2 Localization of necrosis 
In this study the mandible was involved in 100% of the cases, whereas no case was 
diagnosed in maxilla. These findings are concordant with results from other studies 
(Morrish et al. 1981, Beumer et al. 1984, Eggert et al. 1985, Kluth et al. 1988, Curi & 
Dib 1997, Store & Boysen 2000, Thorn et al. 2000, Notani et al. 2003, Chopra et al. 
2011, Gevorgyan et al. 2013). There are many reasons which can explain this 
discrepancy. The mandible has a restricted localized blood supply, which is often 
completely within the radiation field, whereas the maxilla has many anastomoses 
located outside the area of irradiation (Cowgiel 1960, Hoffmeister et al. 1969, Beumer 
et al. 1984, Thorn et al. 2000, Reuther et al. 2003). Furthermore, bone density is 
different between maxilla and mandible and mandible absorbs more amount of 
radiation during RT (Cheng & Wang 1974, Mainous & Hart 1975, Morrish et al. 
1981, Vanderpuye & Goldson 2000, Lambade et al. 2013).  
The posterior region of teeth was affected in 94.8% of the cases whereas the anterior 
only in 23.5% of the cases, a finding in accordance to the literature (Bras et al. 1990, 
Mounsey et al. 1995, Thorn et al. 2000, Reuther et al. 2003). Posterior areas of 
mandible are almost always included in the radiation field during RT of both 
oropharynx and regional lymph nodes (Epstein et al. 1987b, Thorn et al. 2000), as 
well as in the boosted RT fields. They also undergo maximal load during mastication 
and are often subjected to dental extractions which can favor the occurrence of ORN 
(Jereczek-Fossa & Orecchia 2002). In this study, there was no significant association 
between severity of ORN and localization of necrosis in posterior and anterior teeth 
possibly due to the fact that the majority of affected areas were the posterior (94.8%). 
A higher sample size would be needed to highlight a possible association between the 
two variables. This was impossible in the present study as all cases of ORN treated in 
the Department of Oral and Maxillofacial Surgery in Munich (LMU) are included in 
the study. 
12.3 Personal characteristics 
The ratio of males to females in this study was 3.25:1 which is in accordance with the 
male predominance of this disease as reported in other studies (Epstein et al. 1987b, 
Curi & Dib 1997, Epstein et al. 1997, Curi et al. 2000a, Store & Boysen 2000, Notani 
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et al. 2003, Reuther et al. 2003, Goldwasser et al. 2007, Oh et al. 2009, Chopra et al. 
2011, Monnier et al. 2011, Gevorgyan et al. 2013, Tsai et al. 2013). The reason for 
this finding is that males are two to four times more likely to develop oral cancer than 
women, as a result of increased alcohol and tobacco use in male patients (McDowell 
2006). Therefore complications including ORN are more likely to emerge in men. The 
majority of cases were above 55 years old (76.5%) and most of them had stage III 
necrosis, a finding which is in accordance with a study by Epstein et al. (1997). The 
late onset of ORN can be attributed to the late occurrence of OPCs and their 
complications (over 60 years) (Silverman 2001). The reason is that oral tissues have a 
tendency of prolonged exposure to potential carcinogens with advancing age, and 
aging cells may be more susceptible to DNA damage. The result is in agreement with 
other studies (Curi et al. 2000a, Store & Boysen 2000, Goldwasser et al. 2007, Oh et 
al. 2009, Chopra et al. 2011, Monnier et al. 2011, Gevorgyan et al. 2013).  
In accordance with literature, a statistically significant difference in severity of ORN 
with regard to sex as well as age at the time of diagnosis was not demonstrated 
(Chopra et al. 2011, Gevorgyan et al. 2013). This result can be attributed to the great 
superiority of men and also the small age variability in the sample size in the above 
mentioned studies. 
12.4 General health characteristics 
DM is related in the literature with higher risk of ORN (Vanderpuye & Goldson 2000, 
Oh et al. 2009) but is not correlated with the severity of ORN (Gevorgyan et al. 2013). 
In the present study, 60.1% of the cases were suffering from DM. A remarkable point 
is that none of these patients was suffering from stage I necrosis but all of them from 
stage II and III with the majority of them (n=78) suffering from stage III 
osteonecrosis. DM was also identified as a significant predictor for stage III of 
necrosis. 
DM is a group of metabolic diseases in which there are high blood sugar levels over a 
prolonged period. It is divided into two groups: DM type 1 (insulin-dependent) and 
DM type 2 (non insulin-dependent). Wound healing is slowed and can also worsen 
rapidly when the patient is diabetic. There are several factors that influence and 
worsen wound healing in a diabetic patient. These include elevated blood glucose 
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levels which narrow blood vessels as well as poor circulation due to narrowed blood 
vessels which leads to decreased blood flow and oxygen to a wound. The elevated 
blood sugar level decreases the function of red blood cells that carry nutrients to the 
tissue resulting in lower efficiency of white blood cells to fight an infection. Without 
sufficient nutrients and oxygen a wound heals slowly. Moreover, DM lowers the 
efficiency of the immune system against an infection since high glucose levels cause 
immune cells to function ineffectively (Rosenberg 1990, Terranova 1991, Vanderpuye 
& Goldson 2000). By definition, ORN is a non-healing wound with high oxygen 
requirement and a demand for the basic elements of tissue repair. The fact that there 
were a high percentage of stage III cases suffering from DM in the present study may 
explain the reason why DM was a significant predictor for stage III of necrosis. 
Tobacco and alcohol abuse is clearly identified as a risk factor for ORN by many 
studies (Kluth et al. 1988, Schratter-Sahn et al. 1991, Glanzmann & Gratz 1995, Curi 
& Dib 1997, Thorn et al. 2000, Reuther et al. 2003, Shimizutani et al. 2005, Katsura et 
al. 2008, Tsai et al. 2013). Oh et al. (2009) showed that patients with ORN who 
continued to smoke or consume alcohol could not be treated with conservative means 
and needed a surgical resection. However, no association is found between tobacco 
and alcohol abuse and severity of ORN (Chopra et al. 2011, Gevorgyan et al. 2013). 
In the current study 85.0% of cases were active smokers at the time study was 
conducted which is in accordance with the finding of Gevorgyan et al. (2013). About 
two thirds of them (n=97) were suffering from stage III necrosis, 28 from stage II and 
only 5 cases from stage I. On the other side, in the study of Chopra et al. (2011) only 
35% of the patients were active smokers.  
Active smoking was also identified as significant predictor for stage III of necrosis in 
the present study. The association between cigarette smoking and wound healing is 
well known in clinical practice. Toxic constituents of cigarette smoke are responsible 
for delayed wound healing in smokers. Nicotine reduces nutritional blood flow 
resulting in ischemia and impaired healing of injured tissues. Carbon monoxide 
diminishes oxygen transport and metabolism, whereas hydrogen cyanide inhibits 
enzyme systems necessary for oxygen transport at the cellular level (Silverstein 
1992). Moreover, vasoconstriction which occurs owing to smoking may enhance the 
occurrence of mandibular hypovascularisation after RT (Katsura et al. 2008); thus 
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nearly all cases in this study were active smokers (n=130). Taking into account all the 
above the reason for the association found, can be explained. 
Normal alcohol consumption is an average of one to two drinks per day for men and 
one drink per day for women. A drink is one 12 oz. beer, 4 oz. of wine, 1.5 oz. of 80-
proof spirits, or 1 oz. of 100-proof spirits (American Heart Association). In this study, 
excessive alcohol consumption was a significant predictor for stage III of necrosis. 
Ninety-two percent of cases were drinking above normal alcohol consumption and 
most of them were stage II and stage III cases (n=115). Only two cases were suffering 
from stage I necrosis. This percentage is higher than the one reported from Gevorgyan 
et al. (2013) and Chopra et al. (2011) which were 64.3% and 76% respectively. 
Chronic exposure to alcohol impairs wound healing and increases the incidence of 
infection (Guo & DiPietro 2010). It can also cause small vessel vasculitis and 
excessive consumption is associated with increased incidence of DM which affects 
the wound healing (Howard et al. 2004). Furthermore, increased alcohol consumption 
together with smoking may potentiate the effects of other negative factors for ORN 
such as poor oral hygiene (Katsura et al. 2008). 
12.5 Tumor-related characteristics 
In this study 72.6% of the cases were suffering from floor of mouth cancer, followed 
by tongue and pharynx cancer. This finding is in accordance with the literature (Curi 
& Dib 1997, Store & Boysen 2000, Thorn et al. 2000, Notani et al. 2003, Reuther et 
al. 2003, Sulaiman et al. 2003, Lee et al. 2009, Oh et al. 2009, Chopra et al. 2011, 
Monnier et al. 2011, Gevorgyan et al. 2013). Although 60.1% of the cases in the 
present study were diagnosed with advanced tumor size (T3 and T4) 79.1% were 
suffering from stage III and stage IV tumor. Stage IV tumors formed a majority of the 
total (53.6%) which is in accordance with the literature (Reuther et al. 2003, Oh et al. 
2004, Lee et al. 2009, Chopra et al. 2011, Monnier et al. 2011, Gevorgyan et al. 2013, 
Niewald et al. 2013, Tsai et al. 2013). Taking the T classification into account, all but 
two of the patients whose disease was classified as T4 had stage II or III ORN, which 
is also in agreement with the literature (Lee et al. 2009, Chopra et al. 2011, Monnier 
et al. 2011, Gevorgyan et al. 2013). 
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Tumor size (T), overall stage and proximity to bone have been correlated in the 
literature with ORN occurrence. The risk of developing ORN is greater in patients 
with advanced size of tumor and stage of tumor (Bedwinek et al. 1976, Kluth et al. 
1988, Reuther et al. 2003, Oh et al. 2009, Tsai et al. 2013) as well as tumor invasion 
to adjacent bone (Murray et al. 1980c, Morrish et al. 1981, Epstein et al. 1987b). On 
the other hand, tumor size and stage are not associated with the severity of ORN 
(Chopra et al. 2011). It is known that the bigger and the more invasive a tumor is, the 
more extensive surgical treatment and stronger chemotherapy and RT are needed. 
This results to greater damage to the tissues, reducing the vascularity and vitality of 
the adjacent tissues and their ability to heal. Moreover, it is proposed that when the 
tumor invades the adjacent bone, ORN occurrence increases rapidly (Turner et al. 
1996, Curi & Dib 1997). The presented data and the superiority of T3, T4 and stage 
IV patients, can justify the statistically significant association between severity of 
ORN, tumor size and stage of tumor found in the present study, although both of them 
were not included in the significant predictors for stage III of necrosis according to 
the results of logistic regression analysis. 
Oral cavity tumors, especially tumors of the tongue, floor of mouth, alveolar ridge or 
retromolar region contribute to higher risk for developing ORN after irradiation 
(Watson & Scarborough 1938, Curi & Dib 1997, Evensen et al. 2002, Notani et al. 
2003, Reuther et al. 2003, van den Broek et al. 2006), since mandibular bone is 
directly involved in radiation fields and almost always an aggressive and radical 
surgical approach for tumor resection is needed (Curi & Dib 1997). On the other 
hand, tumors of sinonasal or nasopharyngeal areas (Tong et al. 1999, Cheng et al. 
2006, Homma et al. 2009), pharyngeal or laryngeal cancers (Ferguson & Stevens 
2007), present a lower risk for developing ORN. When the primary tumor is adjacent 
to or is overlying bone, the risk of ORN is increased (Rohrer et al. 1979, Murray et al. 
1980b, Tobias & Thomas 1996). In the current study 10.5% of the cases were 
suffering from tumors whose initial location was adjacent to bone. Thus, in 59.5% of 
the cases the mandible was included in initial tumor’s location. Nevertheless, no 
correlation was found between severity of ORN and localization of tumor, regarding 
jaws and oropharynx, as well as soft and hard tissues. This finding is in accordance 
with the literature (Chopra et al. 2011, Gevorgyan et al. 2013) and is probably 
  
 
 
104 Clinical presentation and risk factors of ostoeradionecrosis-Chapter 12 
 
attributed to the fact that a lot of cases were not adjacent to bone or were suffering 
from sinonasal or nasopharyngeal tumors in the present study. 
12.6 Treatment-related characteristics 
All patients in the study received EBRT and none received brachytherapy. For 15 
cases the data regarding the RT were missing. In 10 cases an adjuvant RT was 
necessary and in 3 cases a second adjuvant RT was performed. A significant 
association between the severity of ORN and the radiation setting was not found in 
this study which is in accordance with the literature (Chopra et al. 2011). Although 
studies have shown an association between ORN occurrence and primary surgical 
treatment followed by adjuvant RT (Curi & Dib 1997), there is no reference in the 
literature regarding RT setting and severity of ORN. 
The mean RT dose was 63.4 Gy, relative close to 60 Gy, which has been regarded as 
the level beyond which ORN risk is significantly increased (Schwartz & Kagan 2002, 
Teng & Futran 2005). The dose levels were ranging from 49 to 77 Gy but the majority 
of patients received more than 60 Gy (n=76). Sixty-four cases who received radiation 
over 60 Gy were stage II and III cases, a number which is quite close to the number of 
cases that received less than 60 Gy and were also stage II and III cases (n=52). 
Interestingly none of the patients was treated with new radiation techniques such as 
3D-CRT or IMRT. 
Total radiation dose is thoroughly studied by authors regarding occurrence of ORN. 
Some of them propose and most of them agree that the higher the radiation dose the 
higher the risk of ORN (Beumer et al. 1972, Murray et al. 1980a, Murray et al. 1980b, 
Morrish et al. 1981, Beumer et al. 1983a, Beumer et al. 1984, Withers et al. 1995, 
Reuther et al. 2003, Chang et al. 2007, Lee et al. 2009, Gomez et al. 2011). A 
correlation between incidence of bone necrosis and volume of irradiated mandible has 
been also reported since years (Beumer et al. 1984). Many authors report lower 
incidence of ORN with use of hyperfractionation and accelerated fractionation with 
dose reduction, which is an expected finding due to total dose reduction (Parsons et al. 
1988, Pigott et al. 1993, Mak et al. 1995, Dische et al. 1997, Gwozdz et al. 1997, Fu et 
al. 2000, Mendenhall et al. 2000, Ang et al. 2001, Fallai et al. 2006, Skladowski et al. 
2006, Cummings et al. 2007, Suwinski et al. 2008, Nabil & samman 2012). Other 
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authors mention that an increase in radiation dose alone can not lead to increase in the 
incidence of ORN but its occurence is related to the synergic effect of radiation, 
fractionation and volume of irradiated tissue (Lozza et al. 1997, Jereczek-Fossa & 
Orecchia 2002, Reuther et al. 2003, Studer et al. 2006, Ben-David et al. 2007, Nabil & 
Samman 2011). 
In the present study there was no correlation between radiation dose and severity of 
ORN. This finding is in accordance with the findings of Store & Boysen (2000) and 
Chopra et al. (2011), but is opposed to findings of Gevorgyan et al. (2013). Reasons 
for this contrast are many. First of all, all cases in the current study were treated with 
dose ranging from 49 to 77 Gy and it is proposed that mandible shows a tolerance to 
irradiation doses ranging from 60 to 72 Gy (Emami et al. 1991). Moreover, all cases 
in this study received EBRT with electrons or photons and standard field sizes. Most 
of the patients received a conventional fractionation, which means 2 Gy/fraction, one 
fraction every day and five fractions every week. None of the cases was treated with 
modern techniques of 3D-CRT or IMRT with restriction of irradiated field size and 
reduction of total dose resulting in lower risk of ORN (Studer et al. 2004, Ben-David 
et al. 2007). In contrast, in the study of Gevorgyan et al. (2013) most of the cases were 
radiated with IMRT and only 4 cases were treated with conventional RT. These cases 
were all stage III cases. It can also be argued that another reason to explain the non-
existence of correlation between severity of ORN and total dose in the present study is 
the fact that the number of cases which received less than 60 Gy was almost half the 
size of sample (44.9%). 
CRT is used in patients with evidence of a distant metastasis or in those who are not 
suitable for surgery (Bernier et al. 2005).  Some authors report higher incidence of 
ORN when CRT is used (Hao et al. 1999, Jeremic et al. 2000, Denis et al. 2003, 
Cooper et al. 2004, Budach et al. 2005, Semrau et al. 2006, Stenson et al. 2010). 
However, in previous studies CRT was not statistically significant associated with 
severity of ORN (Chopra et al. 2011, Gevorgyan 2013). In the present study, a great 
majority of cases were treated with concomitant chemotherapy (80.4%). Ninety-six of 
them were diagnosed with stage III ORN. In contrast from 23 patients which were 
suffering from stage I necrosis, only 1 was treated with concomitant chemotherapy. A 
correlation was also found between concomitant chemotherapy and severity of ORN, 
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although it was not included in the significant predictors for stage III of necrosis 
according to the results of logistic regression analysis. There are several reasons for 
this correlation. Firstly, there was a great superiority of patients that were treated with 
chemotherapy and were diagnosed with stage III necrosis (n=96) opposed to stage I 
patients (n=1). Furthermore, most chemotherapeutic drugs are designed to inhibit 
cellular metabolism, rapid cell division, angiogenesis and many pathways that are 
critical for appropriate wound healing. Chemotherapeutic drugs delay cell migration 
into the wound, decrease early wound matrix formation, lower collagen production, 
impair proliferation of fibroblasts, and inhibit contraction of wounds. In addition, 
these agents weaken the immune functions of patients, prevent the inflammatory 
phase of healing and increase the risk of wound infection. Chemotherapy induces 
neutropenia, anemia, and thrombocytopenia, leaving wounds vulnerable to infection 
and causing less oxygen delivery to the wound (Guo & DiPietro 2010). Summarizing 
all the above, it can be concluded that concomitant chemotherapy is likely to weaken 
local immune response, delay the wound healing and favor infections all of which are 
associated with the severity of ORN. 
Time interval between RT and onset of ORN varies in different studies. Most authors 
mention that the majority of cases occur within 3 years after RT (Gowgiel 1960, Marx 
& Johnson 1987, Clayman 1997, Thorn et al. 2000, Notani et al. 2003, Chang et al. 
2007). In the present study the majority of ORN cases (n=95) were diagnosed within 
6 years after RT. Out of these, 55 were diagnosed within 3 years after RT, most of 
them being stage III cases in the course of disease. The cases that were diagnosed 
later than 3 years are also distributed into three stages with a trend of stage III ORN 
being discovered later. This finding is in accordance with the literature (Notani et al. 
2003, Chopra et al. 2011, Gevorgyan et al. 2013). An interesting point is that a great 
majority of cases (33.1%) were diagnosed 6 years after RT with 26 cases among them 
being diagnosed even 9 years after RT. 
There was no statistically significant association between time after RT until the 
occurrence of ORN and the severity of the disease in this study, which is in 
accordance with the literature (Gevorgyan 2013). Nevertheless, it can be argued that 
the later ORN developed, the more it progressed (advanced stage). The explanation is 
the reduction in biologic activity which develops with time after RT (Bedwinek et al. 
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1976, Larson et al. 1983, Marx 1983a & 1983b, Epstein et al. 1987a). This means that 
ORN which develops early may still have more biologic activity to heal 
sponataneously and lesions might be localized. On the other hand, late-onset may 
have less biologic activity and lesion might become serious. 
12.7 Oral health condition before radiotherapy and factors that 
contributed to the onset of osteoradionecrosis 
It is well known that a good oral and dental health condition is an important 
requirement before starting RT. For this reason, all cancer centers, oral and 
maxillofacial clinics and radiology centers should refer their patients to dental control 
before RT starts. The same strict requirements are applied in the Department of Oral 
and Maxillofacial Surgery in Munich (LMU). Nevertheless, in the present study 
56.9% of the cases were not subjected to dental examination and treatment before RT. 
Out of these only one was diagnosed with stage I ORN, whereas 71 (46.4% of cases) 
were suffering from stage III necrosis. This result can be interpreted as bad oral 
condition before RT by most of the cases (56.9%) with the majority of them suffering 
from stage III necrosis. The finding is in accordance with the literature (Murray et al. 
1980b, Morrish et al. 1981, Kluth et al. 1988, Jereczek-Fossa & Orecchia 2002, Oh et 
al. 2009, Chopra et al. 2011, Monnier et al. 2011). 
Many authors have proved that risk of developing ORN is increased in patients with 
poor oral health (Carl et al. 1972, Regezi et al. 1976, Murray et al. 1980b, Murray et 
al. 1980c, Beumer et al. 1984, Kluth et al. 1988, Bachmann et al. 1996, Katsura et al. 
2008). In the study by Katsura et al. (2008) oral health conditions predisposing to 
ORN were: periodontal pocket depth >5mm, dental plaque score >40% alveolar bone 
loss >60% and a grade 3 radiographic periodontal status. Although occurrence of 
ORN is dependent not only on the extent of radiation damage to bone but also on 
patient’s dental health (Nabil & Samman 2012), oral health has not been yet 
associated with severity of ORN (Chopra et al. 2011). Although dental examination 
and treatment before RT was not included in the significant predictors for stage III of 
necrosis according to the results of logistic regression analysis, there was a significant 
correlation between this and the severity of ORN. There are two fundamental 
explanations for this finding. First of all, there was a great superiority of patients 
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suffering from stage III necrosis who did not have good oral health before RT 
opposed to patients suffering from stage I necrosis. Moreover, more traumatic dental 
events after RT are to be expected in patients with bad oral hygiene before RT 
increasing the possibilities of ORN. 
In the present study 59.5% of the cases occurred due to a specific cause whereas 
40.5% of the cases occurred spontaneously. Interestingly, the majority of 
spontaneously occurring cases were stage III cases (50 out of 62) whereas in the cases 
of specific cause a more normal distribution is seen among the three stages, although 
most of them were stage III cases (49 out of 91). Dental treatment/Local pathological 
condition was identified as significant predictor for stage III of necrosis in this study. 
This finding is opposed to findings from other similar studies (Chopra et al. 2011, 
Gevorgyan et al. 2013). The reason is that the sample size in the present study is much 
bigger than in other studies with a great majority of cases occurring spontaneously. 
Thus, there is no focus in other studies to spontaneously occurring ORN cases but 
only to ORN cases occurring due to dental extraction before or after RT. 
As mentioned above, in the present study causes of ORN included many variables 
such as extraction of a tooth, implantation, denture irritation or even a local 
pathological condition such as marginal or apical periodontitis. A significant 
correlation between the severity of ORN and these variables was found, although they 
were not included in the significant predictors for stage III of necrosis according to 
the results of logistic regression analysis. Extraction of a tooth either alone or in 
combination with other dental treatment constituded the main cause (91%) in the 
occurrence of ORN cases due to dental treatment (56 cases). Teeth extractions play a 
crucial role in the pathogenesis of ORN (Hansen et al. 2006a) and they are proposed 
as the most common cause of trauma-induced ORN of the jaws in 60-89% of the 
cases (Murray et al. 1980a, Marx & Johnson 1987). The reason is that after dental 
extraction a wound requires protein syntheses which are obtained by cellular activity 
and vascular events (Maxymiw et al. 1991). However, ionizing radiation promotes 
irreversible cellular and vascular damage resulting in hypoxic, hypocellular and 
hypovascular tissue. This fact can drastically affect the reparation process (Beumer et 
al. 1976, Beumer et al. 1983a, Beumer et al. 1983b, Beumer et al. 1984, Koga et al. 
2008a) and result to ORN. 
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Regarding ORN cases related to extractions performed before RT, most studies show 
low incidence (Bedwinek et al. 1976, Epstein et al. 1987b, Sulaiman et al. 2003, Oh et 
al. 2004, Koga 2008b). In several studies postirradiation dental extractions are 
associated with high rates of ORN (Beumer et al. 1972, Morrish et al. 1981, Beumer 
et al. 1984, Marx & Johnson 1987, Thorn et al. 2000). Most recent data show a 
downward trend of ORN risk after extractions (Nabil & Samman 2011). Implantation 
is also associated with ORN occurrence (Granström et al. 1993, Taylor and 
Worthington 1993, Franzen et al. 1995, Arcuri et al. 1997). In the present study 5 
cases of ORN occurred due to implantation. Most dental surgeries (n=40) that led to 
ORN were performed after RT opposed to these performed before RT (n=10). There 
was no statistical significant association between severity of necrosis and time of 
occurrence of dental surgey, a finding which is in accordance with the literature 
(Chopra et al. 2011). A possible reason for this finding is the small number of ORN 
cases due to dental surgery compared to spontaneously occurring ORN cases. The 
association between the variables could possibly be detected with a higher number of 
ORN cases owing to extractions.  
Concerning ORN cases due to local pathological condition (n=35) the majority of 
them were attributed to marginal periodontitis (82.9%) followed by denture irritation 
(8.6%). Many authors refer marginal periodontitis (Thiel 1989, Niewald et al. 1996, 
Curi & Dib 1997, Jereczek-Fossa & Orecchia 2002, Katsura et al. 2008, Oh et al. 
2009) as well as denture irritation (Curi & Dib 1997, Thorn et al. 2000, Oh et al. 
2009) as risk factors for occurrence of ORN. The reason is that these patients are in 
greater danger for trauma after RT than patients without local pathological conditions 
(Carl et al. 1972, Regezi et al. 1976, Murray et al. 1980b, Murray et al. 1980c, 
Beumer et al. 1984, Kluth et al. 1988, Bachmann et al. 1996, Katsura et al. 2008). 
Taking into account the entire above, special attention must be paid to pretreatment 
planning of dental therapy and post-treatment controls. Particular care must be taken 
with extraction techniques, dental hygiene, adequate healing time for teeth extracted 
before and after RT and protection of tooth with special fluoride devices (Reuther et 
al. 2003). Every patient who will be treated with RT should be subjected to 
pretreatment dental control so that periodontal disease and other causes of ORN will 
be eliminated and unsalvageable teeth will be extracted. The dentist is also obliged to 
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provide the patient with explanations for the importance of dental management and a 
“close follow-up” schedule. All these measures can reduce the likelihood of ORN and 
its severity. 
12.8 Treatment of osteoradionecrosis 
Regarding the treatment of ORN various different methods have been reported 
depending on several factors such as presentation of necrotic lesion, response to 
conservative nonsurgical therapy, general health of the patient, prognosis for 
successful management of the cancer, wishes of the patient, dose of irradiation and 
time interval after RT (Epstein et al. 1987a, Kawahara et al. 1987, Notani et al. 2003). 
They can be categorized in two groups: conservative (improvement of oral hygiene, 
antibiotics, analgesics, HBO) and surgical. Some investigators agree that initial 
treatment of ORN should be conservative, since failure of this course can always be 
followed with a more radical approach (Niebel & Neeman 1957, MacComb 1962, 
Hahn & Gorgill 1966), while others believe that a radical approach should be 
instituted at initial diagnosis (MacDougall et al. 1963, Marchetta et al. 1967).  
In the present study the surgical treatment, outmatches the conservative treatment 
independent of stage of necrosis. Overall, 7.8% of the cases were treated in a 
conservative manner, 69.9% were treated surgically and 22.2% with combination of 
them. It should be noted that in stage I where the necrosis is not extended, 60.9% of 
the patients were treated surgically, 17.4% conservatively and 21.7% with both 
methods. This finding is opposed to the majority of recent studies, in which authors 
advocate a treatment approach according to the stage of necrosis (Jacobson et al. 
2010, Chopra et al. 2011, Gevorgyan et al. 2013), with surgical treatment used only in 
advanced stages of necrosis. The reason for this is that in the Department of Oral and 
Maxillofacial Surgery in Munich (LMU) the treatment policy includes a more radical 
approach than conservative treatment due to better results observed in these cases. 
  
 
 
 
Chapter 13 
 
Conclusion 
In conclusion, osteonecrosis remains a severe problem in RT of the jaws. Previous 
studies on the topic have focused on risk factors associated with the cause and 
incidence of ORN; the present study aimed to focus on factors that are predictive of 
the severity of mandibular ORN. The majority of cases was diagnosed as stage III 
necrosis and was male. The mandible was affected in all cases; no case was diagnosed 
in the maxilla. There was a predominance of the disease in the posterior region. All 
cases were treated with radiotherapy and 80.4% of them with concomitant 
chemotherapy. The affected patients mainly had poor oral hygiene before the onset of 
RT and approximately two thirds of the cases occured either after dental treatment or 
in oral regions with a local pathological condition. The main symptom was bone 
exposure followed by wound healing disorder, swelling and pain. The majority of the 
cases were treated surgically, independent of the stage of necrosis. DM, active 
smoking, alcohol and dental treatment/local pathological condition were identified as 
significant predictors for stage III necrosis. Based on these findings, prospective 
studies should be conducted, in order to understand the risk factors, the severity and 
the pathophysiology of ORN better and to improve the treatment strategies for this 
complication.  
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